


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:45Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407833" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407833</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>melman</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Melanoma Manag</journal-id><journal-id journal-id-type="iso-abbrev">Melanoma Manag</journal-id><journal-id journal-id-type="pmc-domain-id">3443</journal-id><journal-id journal-id-type="pmc-domain">melman</journal-id><journal-title-group><journal-title>Melanoma Management</journal-title></journal-title-group><issn pub-type="ppub">2045-0885</issn><issn pub-type="epub">2045-0893</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407833</article-id><article-id pub-id-type="pmcid-ver">PMC12407833.1</article-id><article-id pub-id-type="pmcaid">12407833</article-id><article-id pub-id-type="pmcaiid">12407833</article-id><article-id pub-id-type="pmid">40878046</article-id><article-id pub-id-type="doi">10.1080/20450885.2025.2545167</article-id><article-id pub-id-type="publisher-id">2545167</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project</article-title><alt-title alt-title-type="left-running-head">C. Gebhardt et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gebhardt</surname><given-names initials="C">Christoffer</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AN0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Debus</surname><given-names initials="D">Dirk</given-names></name><xref rid="AF0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rohrer</surname><given-names initials="P">Peter</given-names></name><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>K&#228;hler</surname><given-names initials="KC">Katharina C.</given-names></name><xref rid="AF0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koch</surname><given-names initials="L">Lukas</given-names></name><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Terheyden</surname><given-names initials="P">Patrick</given-names></name><xref rid="AF0005" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="VA">Van Anh</given-names></name><xref rid="AF0006" ref-type="aff">f</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE)</institution>, Hamburg, <country>Germany</country></aff><aff id="AF0002"><label>b</label><institution>Department of Dermatology, University Hospital of the Paracelsus Medical Private University</institution>, <city>N&#252;rnberg</city>, <country>Germany</country></aff><aff id="AF0003"><label>c</label><institution>Department of Dermatology and Venereology, Medical University of Graz</institution>, <city>Graz</city>, <country>Austria</country></aff><aff id="AF0004"><label>d</label><institution>Department of Dermatology, Venereology and Allergology, UniversityHospital Schleswig-Holstein</institution>, <city>Kiel</city>, <country>Germany</country></aff><aff id="AF0005"><label>e</label><institution>Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein</institution>, <city>L&#252;beck</city>, <country>Germany</country></aff><aff id="AF0006"><label>f</label><institution>University Hospital for Dermatology, Venereology &amp; Allergology, Medical University Innsbruck</institution>, <city>Innsbruck</city>, <country>Austria</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Christoffer Gebhardt <email xlink:href="mailto:ch.gebhardt@uke.de">ch.gebhardt@uke.de</email><institution>Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE)</institution>, <addr-line>Martinistrasse 52</addr-line>, <city>Hamburg</city><postal-code>20246</postal-code>, <country>Germany</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>12</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">482436</issue-id><elocation-id>2545167</elocation-id><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="received"><date><day>21</day><month>5</month><year>2025</year></date></event><event event-type="accepted"><date><day>5</day><month>8</month><year>2025</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>28</day><month>8</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>28</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IMMT_12_2545167.pdf"/><self-uri content-type="pdf" xlink:href="IMMT_12_2545167.pdf"/><abstract><title>Abstract</title><p>The management of advanced, unresectable, or metastatic BRAFV600-mutated melanoma is complex, particularly regarding therapy sequencing with targeted therapies (TT) and immune checkpoint inhibitors (ICI). The REMINISCENCE project aimed to enhance individualized therapy approaches by analyzing case reports of patients undergoing encorafenib and binimetinib (EB) therapy. This report discusses three melanoma patients with brain metastases treated in Germany and Austria, emphasizing personalized treatment strategies in BRAFV600-mutated melanoma, particularly when both ICI and TT are available. The timing for transitioning between therapies remains contentious, with many patients experiencing disease progression during or after adjuvant therapy. Findings from clinical trials like DREAMseq, SECOMBIT, EBIN, and ImmunoCobiVem may not directly apply to this evolving clinical landscape due to the impact of prior therapies on the tumor microenvironment. The variations in trial designs further complicate sequencing strategies. Emerging methods, such as early circulating tumor DNA (ctDNA)-guided approaches, present potential pathways for personalized treatment. Ongoing research into sequencing therapy is crucial for improving clinical outcomes. To determine the most effective treatment sequences based on individual medical histories, genetic profiles, and treatment goals, there is an urgent need for prospective biomarker-driven clinical trials.</p></abstract><abstract abstract-type="plain-language-summary"><title>KEY POINTS/HIGHLIGHTS</title><p>
<bold>
<italic toggle="yes">Why was the study undertaken?</italic>
</bold>
<list list-type="bullet"><list-item><p>There is only limited data on multimorbid real-world patients who are often excluded from clinical trials and the best sequence for these patients, including targeted therapies (TT) and immunotherapies (ICI) remains unclear.</p></list-item><list-item><p>The REMINISCENCE project aimed to collect exemplary single case reports of advanced real-world melanoma patients with a therapy sequence including ongoing or completed encorafenib and binimetinib (EB) therapy as a basis for scientific discussions.</p></list-item></list>
</p><p>
<bold>
<italic toggle="yes">What does this study add?</italic>
</bold>
<list list-type="bullet"><list-item><p>This report describes and discusses treatment sequences and outcomes in exemplary real-world cases of multimorbid patients with progression during ICI treatment or with preexisting autoimmune disease, rapidly progressing disease, and/or brain metastasis.</p></list-item><list-item><p>Treatment decisions are discussed in the context of the new ESMO 2024 melanoma guidelines, literature, and ongoing research.</p></list-item><list-item><p>An outlook on the latest study results for sequencing is given and discussed.</p></list-item></list>
</p><p>
<bold>
<italic toggle="yes">What are the implications of this study for disease understanding and/or clinical care?</italic>
</bold>
<list list-type="bullet"><list-item><p>Real-world sequencing efficacy data in multimorbid patients with asymptomatic and symptomatic brain metastasis, with preexisting autoimmune disease, and patients with high tumor burden and rapidly progressing disease are presented.</p></list-item><list-item><p>The best sequence for each patient is based on patient characteristics, medical history and a careful benefit-risk assessment.</p></list-item><list-item><p>As TT has shown quick responses even in frail patients with high tumor burden, while ICI showed slow but long-lasting benefits for BRAF-mut patients, future approaches will investigate run-in phases with TT and early switches (without progression) to ICI.</p></list-item></list>
</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Oncology</kwd><kwd>BRAF-mutated melanoma</kwd><kwd>targeted therapies</kwd><kwd>real-world data</kwd><kwd>clinical practice</kwd><kwd>sequencing in melanoma treatment</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Fondation Pierre Fabre/Pierre Fabre Pharma GmbH</institution></institution-wrap></funding-source></award-group><funding-statement>Funding of REMINISCENCE trial: Fondation Pierre Fabre/Pierre Fabre Pharma GmbH, Freiburg, Germany.</funding-statement></funding-group></support-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="17"/><word-count count="10880"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><label>1.</label><title>Introduction</title><p>Melanoma is one of the most common cancers in both men and women in the EU and one of the most frequent causes of cancer death [<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref>]. Melanoma accounts for annually more than 16,000 deaths in Europe and is an important public economic and health burden due to its continuously increasing incidence and its high mortality and costs [<xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0004" ref-type="bibr">4</xref>]. Considerable differences in 5-year relative survival rates have been observed within the EU (Nordic or Western countries &gt;&#8201;90%; Eastern Europe &lt;&#8201;60% for people diagnosed in the past decade) [<xref rid="CIT0004" ref-type="bibr">4</xref>]. Metastatic spread is the primary cause of death in melanoma patients. Metastases affect regional lymph nodes, such as satellite or in-transit lesions, or distant organs including the brain. Lymph or blood flow and chemotaxis guide the colonization of melanoma cells at different sites. Cutaneous melanoma has one of the highest mutational rates among all solid tumors [<xref rid="CIT0005" ref-type="bibr">5</xref>].</p><p>Due to the demographic shift, a further increase in skin melanoma incidence and an increase in the social and economic burden due to this disease are expected [<xref rid="CIT0004" ref-type="bibr">4</xref>].</p><p>Most melanoma skin cancers are diagnosed in stage I (AJCC [American Joint Committee on Cancer], 8th edition) [<xref rid="CIT0006" ref-type="bibr">6</xref>] and related to a good prognosis (with a 10-year overall survival rate of 96%) [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Once the tumor spreads to other organs, prognosis worsens dramatically.</p><p>More than 40% of patients with metastatic melanoma develop brain metastases (MBM) in the course of the disease. Autopsies revealed MBM even in more than 70% patients [<xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0009" ref-type="bibr">9</xref>].</p><p>About 40% to 50% of patients with cutaneous melanomas harbor an activating <italic toggle="yes">BRAF</italic>-mutation that promotes tumor proliferation through the mitogen-activated protein kinase (MAPK)/ERK signaling pathway [<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref>]. Of these, 70% to 88% account for the most common mutation in the <italic toggle="yes">BRAF</italic> gene in melanoma localized in exon 15 &#8211; codon 600 &#8211; of the <italic toggle="yes">BRAF</italic> gene, with a substitution of amino acid glutamic acid for valine at position 600 (V600E) and another 10% to 20% for the less active V600K [<xref rid="CIT0012" ref-type="bibr">12</xref>,<xref rid="CIT0013" ref-type="bibr">13</xref>]. The discovery of <italic toggle="yes">BRAF <sup>V600</sup></italic> as a therapeutic target has been a milestone in treating advanced melanoma.</p><p>Clinical trials investigating the combination of <italic toggle="yes">BRAF</italic> and <italic toggle="yes">MEK</italic> inhibitors in <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutant melanoma patients reported a prolongation in both PFS (progression-free survival) and OS (overall survival) compared with single-agent <italic toggle="yes">BRAF</italic> inhibitors leading to a 5-year prolonged PFS rate of 14% to 23% and a prolonged 5-year OS rate of 31% to 36% [<xref rid="CIT0014" ref-type="bibr">14&#8211;18</xref>]. In fact, the combination of <italic toggle="yes">BRAF</italic> and MEK [<xref rid="CIT0015" ref-type="bibr">15&#8211;19</xref>] inhibition as well as blockade of programmed cell death protein-1 (PD-1) and both dual PD-1 and cytotoxic T lymphocyte antigen-4 (CTLA-4) as well as dual PD-1 and lymphocyte-activation gene 3 (LAG-3) inhibition offer clinical benefit to metastatic cutaneous melanoma patients and are approved in Europe and the USA (see corresponding prescription information and guideline recommendations, the combination of PD-1 and LAG-3 inhibitors is approved in Europe but only marketed in some countries) [<xref rid="CIT0020" ref-type="bibr">20&#8211;30</xref>]. In addition, combination therapy is associated with lower toxicity compared to monotherapy with BRAF or MEK inhibitors alone, as the paradoxical activation of the MAP kinase signaling pathway (as observed with monotherapy with BRAF inhibitors) is inhibited by MEK inhibitors.</p><p>At present, the following BRAF/MEK combination therapies are approved and available for the treatment of unresectable advanced or metastatic <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated melanoma in Europe: dabrafenib&#8201;+&#8201;trametinib (DT) [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>], vemurafenib&#8201;+&#8201;cobimetinib (VC) [<xref rid="CIT0025" ref-type="bibr">25</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>], encorafenib&#8201;+&#8201;binimetinib (EB) [<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>]. Additionally, immune checkpoint inhibition (ICI) with anti-PD-1 antibodies (nivolumab [N] and pembrolizumab [P]) and CTLA-4 antibody (ipilimumab [IPI]), as well as N&#8201;+&#8201;relatlimab ([REL], a LAG-3 inhibitor), is currently available for the treatment of unresectable or metastasized melanoma in Europe. Data show consistent efficacy for both monotherapy (N: CheckMate-066 [<xref rid="CIT0031" ref-type="bibr">31</xref>]; P: KEYNOTE-006 [<xref rid="CIT0032" ref-type="bibr">32</xref>]) and combination therapy (N&#8201;+&#8201;IPI: CheckMate-067 [<xref rid="CIT0033" ref-type="bibr">33</xref>], N&#8201;+&#8201;REL: RELATIVITY-047 [<xref rid="CIT0034" ref-type="bibr">34</xref>,<xref rid="CIT0035" ref-type="bibr">35</xref>]) irrespective of mutational status. ICI and BRAF/MEK inhibitors (targeted therapies: TT) changed the treatment of this disease.</p><p>Currently, there is no universally applicable recommendation available regarding the best sequence for <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated advanced melanoma, including TT and ICI. According to the current European consensus guideline, ICI shall be offered as first-line irrespective of <italic toggle="yes">BRAF</italic> status in advanced melanoma patients. However, in particular scenarios, first-line therapy with TT should be offered as an alternative to patients harboring a <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutation [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref>].</p><p>Thus, to optimize outcomes, a personalized approach to treatment decisions based on the patient&#8217;s medical history, the course of the disease, and other patient characteristics need to be considered using the full armamentarium of treatment approaches approved for these patients.</p><p>This article reports on distinct treatment approaches in particular scenarios from clinical practice and places them in the context of current guidelines, expert recommendations, and emerging clinical trial data.</p></sec><sec disp-level="1" id="S0002"><label>2.</label><title>Metastatic BRAF-mutated melanoma- patient cases from clinical practice</title><p>The retrospective case report project REMINISCENCE aimed to collect exemplary single case reports of patients receiving combination therapy with EB as a basis for training and scientific discussions [<xref rid="CIT0037" ref-type="bibr">37</xref>,<xref rid="CIT0038" ref-type="bibr">38</xref>]. Illustrative cases of adult patients with locally advanced, unresectable, or metastatic <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated melanoma with a therapy sequence including ongoing or completed EB combination therapy were selected by treating physicians. Eligible patients were documented retrospectively using standardized case report forms after patients&#8217; informed consent. Since there was no standard definition of symptomatic MBM [<xref rid="CIT0039" ref-type="bibr">39</xref>], the definition for symptomatic and asymptomatic MBM was not documented in these cases. The following 3 cases (<xref rid="F0001" ref-type="fig">Figure 1</xref>) illustrate the personalized treatment of patients with metastatic <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated melanoma:</p><fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>Exemplary patient cases 1, 2, 3. <italic toggle="yes">Abbreviations:</italic> 1&#8201;L, First line; 2&#8201;L, Second line; AJCC, American Joint Committee on Cancer; ALT, Alanine amino transferase; AST, Aspartat amino transferase; BR: best resonse; CNS, central nervous system; CR, complete remission; EB, Encorafenib&#8201;+&#8201;Binimetinib; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GOT, glutamyl-oxaloacetate transaminase; GPT, glutamyl-pyruvate transaminase; IFN, Interferone; LDH, lactate dehydrogenase; PD, Progress; PR, partial remission; SRS, stereotaxis radiosurgery; T-VEC, Talimogen lapherparepvec; ULN, upper limit of normal; UNK, unknown.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IMMT_A_2545167_F0001_C.jpg"/></fig><sec disp-level="2" id="S0002-S2001"><label>2.1.</label><title>Patient 1: 59&#8201;years old, multimorbid male progressing under first-line therapy</title><p>Medical history: A 59-year-old male patient with a medical history of myocardial infarction (06/2018), arterial hypertension (08/2018), and heparin-induced thrombocytopenia (HIT Type II, 09/2018) was diagnosed in 11/2017 with advanced <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated stage IV melanoma (AJCC v8: T4a, N3c, M1d). The patient presented with ECOG performance status 0 and loco-regional (satellite lesions and multiple lymph node metastases) and distant metastases in lymph nodes, lungs, liver, and central nervous system (CNS, n&#8201;=&#8201;1; maximal size: 6&#8201;mm). Elevated levels of S100 (&gt;2x ULN) and LDH (1-2x ULN) were documented.</p><p>First-line therapy in advanced melanoma: After resection of the extensive primary tumor (in sano), treatment with N&#8201;+&#8201;IPI in the first-line setting was initiated in 11/2017. The ICI resulted in a partial remission (PR). Complete remission (CR) was achieved in the CNS metastasis (following stereotaxis with 20&#8201;Gy;) and in the extra-regional lymph node metastases. A stable disease (SD) was reached for the remaining distant metastases. The ICI was discontinued in 02/2018 due to persistent toxicity (pancreatitis grade 2, 01-05/2018; persistent vitiligo grade 1 since 04/2018). After a therapy break from 03/2018 to 06/2019, the tumor progressed (05/2019; stage IV AJCC v8: T4a, N3c, M1d) with further distant metastases (including a new CNS metastasis and an axillary loco-regional lymph node metastasis of 4.2&#8201;cm on the left side). A subsequent stereotaxis of the CNS metastasis (06/2019; n&#8201;=&#8201;1; max.15&#8201;mm) led to CR. Stereotactic radiosurgery (SRS) is a crucial treatment for melanoma patients with isolated MBM and is preferred over whole brain radiotherapy (WBRT). Treatment decisions are based on patient informed consent and the credo: Treat as effectively as possible while maintaining the best quality of life (QoL).</p><p>Second-line therapy in advanced melanoma: Second-line therapy with encorafenib (450&#8201;mg once daily, QD) and binimetinib (45&#8201;mg twice daily, BID) was started 07/2019. Stable disease was obtained in lymph nodes and distant metastases. A sustained therapeutic effect with SD (and CR in the CNS metastasis) was observed (for 15.7&#8201;months, therapy was ongoing at the end of the observation period 09/2020) with no documented adverse events.</p></sec><sec disp-level="2" id="S0002-S2002"><label>2.2.</label><title>Patient 2: multimorbid 82-year-old female with an autoimmune disease</title><p>Medical history: An 82-year-old female presented in 2021 with myasthenia gravis (MG, following thymectomy), hypertension, good ECOG Performance Status (ECOG PS 0), and moderate LDH as well as S100 increase (1&#8211;2x ULN). Melanoma stage IV was diagnosed in 10/2019 (AJCC v8: T4b, N0, M1d) with a single CNS metastasis (size: 9&#8201;mm) and confirmed <italic toggle="yes">BRAF</italic><sup>V600K</sup>- mutation. Subsequently, the primary (R0) and CNS metastasis (R2) resections were performed, followed by stereotactic treatment of the CNS metastasis in 11/2019.</p><p>First-line therapy in advanced melanoma: The interdisciplinary tumor board considered MG a contraindication for ICI in first-line due to the high risk of worsening this autoimmune disease [<xref rid="CIT0040" ref-type="bibr">40&#8211;43</xref>] Treatment with a combination of TT was initiated in 01/2020 with encorafenib (450&#8201;mg QD) and binimetinib (45&#8201;mg BID) due to the combination&#8217;s safety profile. The best response to treatment was PR. The patient was still on treatment at the end of the documentation (12.2&#8201;months; 01/2021).</p><p>During combination therapy, the following drug-related adverse events were observed: CK increase (grade 1; persistent since 01/2020), ALT increase (grade 1; 03-10/2020), AST increase (grade 1; 04-12/2020), and exanthema (grade 1; 04-06/2020). No treatment modifications were necessary. The combination therapy showed good therapeutic success (PR) despite an initially poor prognosis and adequate tolerability, with only mild adverse events.</p></sec><sec disp-level="2" id="S0002-S2003"><label>2.3.</label><title>Patient 3: 75-year-old male patient with aggressive course of the disease (high LDH)</title><p>Medical history: The 75-year-old male was diagnosed with stage IIb melanoma (AJCC v8: T3b, N0, M0, no ECOG performance status documented) in 11/2014. Surgery of the primary was performed with no residual disease (R0). Additionally, adjuvant therapy with INF&#945; (3 x 3 Mio IE) was given from 01/2015 to 06/2016, resulting in no evidence of disease.</p><p>In 07/2020, tumor recurrence was diagnosed with stage IV melanoma (AJCC v8: T3a, N0, M1d), no loco-regional metastasis, distant metastases in lungs, extra-regional lymph nodes and CNS (n&#8201;=&#8201;7, maximum size: 22&#8201;mm). Detection of <italic toggle="yes">BRAF</italic><sup>V600K</sup>-mutation of the primary was documented. LDH and S100 were elevated (S100&#8201;&gt;&#8201;1&#8211;2x ULN; LDH&#8201;&gt;&#8201;2x ULN). The patient presented with a slightly impaired general condition (ECOG performance status 1). CNS metastases were treated in 08/2020 by stereotactic radiotherapy with a total dose of 35&#8201;Gy.</p><p>First-line therapy in advanced melanoma: Due to the high tumor burden and the rapidly progressive disease as well as the poor prognosis (high LDH, multiple metastases including CNS metastases), the decision for a TT was taken: encorafenib (450&#8201;mg QD) and binimetinib (45&#8201;mg BID) were initiated in 09/2020. The best response with EB was PR (incl. CNS). At the end of the documentation, the patient was still under treatment (01/2021).</p><p>Treatment was interrupted for a total of 14&#8201;days due to adverse events (poor grade 3 general condition, severe, 09-10/2020, and grade 2 fever, 09-10/2020) with subsequent resumption of therapy without dose reduction.</p><p>Further adverse events documented during treatment include an Escherichia coli urinary tract infection grade 2 (09/2020), taste disorder grade 2 (09-10/2020), and loss of appetite grade 2 (09-10/2020). All adverse events subsided without consequences. Persistent ALT, AST, glutamyl-oxaloacetate transaminase (GOT), and glutamyl-pyruvate transaminase (GPT) elevation grade 1 was noted (from 11/2020 until the end of documentation 01/2021). Under the systemic first-line therapy with EB, PR, and thus a sustained therapeutic success occurred with adequate tolerability.</p></sec></sec><sec disp-level="1" id="S0003"><label>3.</label><title>Cases in the context of current guideline recommendations and ongoing studies</title><p>Current guidelines [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>] encourage individualized therapy and shared decision-making, based on assessment of the patient&#8217;s medical condition, potential contraindications, and disease severity. Accordingly, in the case of <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated metastatic melanoma, both treatment with ICI and with TT should be considered.</p><p>Here, we discuss three scenarios and the basis of therapy decision-making.</p><sec disp-level="2" id="S0003-S2001"><label>3.1.</label><title>Patient 1: treatment until progression</title><p>The patient showed signs of ICI-related toxicities, leading to ICI combination therapy interruption and disease progression. Choosing a second-line treatment depends on the strategies used during neoadjuvant, adjuvant, and first-line metastatic therapies, as well as the BRAF<sup>V600</sup> mutational status of the disease. Considering the performance during the ICI pretreatment and the presence of a <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutation, guidelines recommend BRAF/MEK inhibitors in the second-line [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>]. Although an ICI rechallenge could also be an option, particularly as the patient benefited from the first-line therapy, with a response at the time of discontinuation, evidence for this treatment approach is limited. Pembrolizumab second-line data from the KEYNOTE 006 trial cross-over showed that for patients receiving second-line P, the median OS was 23.5 (16.8&#8211;34.2), and the 5-year OS rate was 32.3% (25.5&#8211;39.3). This trial also showed that IPI monotherapy second-line could be an option for patients progressing on anti-PD-1 antibody pretreatment [<xref rid="CIT0033" ref-type="bibr">33</xref>,<xref rid="CIT0045" ref-type="bibr">45</xref>]. Data regarding nivolumab in the CheckMate 067 trial, showed efficacy for 152 patients in the N arm receiving subsequent systemic therapy with another ICI (n&#8201;=&#8201;105) [<xref rid="CIT0032" ref-type="bibr">32</xref>].</p><p>However, a systematic review showed that ICI rechallenge after immune-related adverse events worsens safety and lowers efficacy outcomes compared with initial ICI treatment [<xref rid="CIT0046" ref-type="bibr">46</xref>,<xref rid="CIT0047" ref-type="bibr">47</xref>]. The TT provides an effective alternative to ICI second-line following ICI (<xref rid="t0001" ref-type="table">Table 1</xref>). Based on a thorough benefit-risk assessment and their center&#8217;s experience, the treating physicians decided to start treatment with EB.</p><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Efficacy of approved and available combination therapies in patients with BRAF-mutated advanced melanoma.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Trial</th><th align="center" colspan="1" rowspan="1">Drugs</th><th align="center" colspan="1" rowspan="1">Median OS (mo)</th><th align="center" colspan="1" rowspan="1">5-year OS rate %*</th><th align="center" colspan="1" rowspan="1">7-year OS rate**</th><th align="center" colspan="1" rowspan="1">Median PFS (mo)</th><th align="center" colspan="1" rowspan="1">5-year PFS rate %*</th><th align="center" colspan="1" rowspan="1">7-year PFS rate %**</th><th align="center" colspan="1" rowspan="1">ORR</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Combi-D</td><td align="left" colspan="1" rowspan="1">Dabrafenib&#8201;+&#8201;trametinib</td><td align="char" char="." colspan="1" rowspan="1">25.8</td><td align="char" char="." colspan="1" rowspan="1">32%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">10.2</td><td align="char" char="." colspan="1" rowspan="1">17%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">69%</td><td align="left" colspan="1" rowspan="1">* Long et&#160;al., 2015 [<xref rid="CIT0016" ref-type="bibr">16</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01584648">NCT01584648</ext-link></td><td align="left" colspan="1" rowspan="1">Dabrafenib</td><td align="char" char="." colspan="1" rowspan="1">18.7</td><td align="char" char="." colspan="1" rowspan="1">27%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">8.8</td><td align="char" char="." colspan="1" rowspan="1">13%</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">54%</td><td align="left" colspan="1" rowspan="1">*Robert et&#160;al. 2019 [<xref rid="CIT0019" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Combi-V</td><td align="left" colspan="1" rowspan="1">Dabrafenib&#8201;+&#8201;trametinib</td><td align="char" char="." colspan="1" rowspan="1">26.0</td><td align="char" char="." colspan="1" rowspan="1">36%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">11.1</td><td align="char" char="." colspan="1" rowspan="1">20%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">64%</td><td align="left" colspan="1" rowspan="1">*Robert et&#160;al. 2015 [<xref rid="CIT0015" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01597908">NCT01597908</ext-link></td><td align="left" colspan="1" rowspan="1">Vemurafenib</td><td align="char" char="." colspan="1" rowspan="1">17.8</td><td align="char" char="." colspan="1" rowspan="1">23%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">7.3</td><td align="char" char="." colspan="1" rowspan="1">9%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">51%</td><td align="left" colspan="1" rowspan="1">*Robert et&#160;al. 2019 [<xref rid="CIT0019" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CoBRIM</td><td align="left" colspan="1" rowspan="1">Vemurafenib&#8201;+&#8201;Cobimetinib</td><td align="char" char="." colspan="1" rowspan="1">22.5</td><td align="char" char="." colspan="1" rowspan="1">31%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">12.6</td><td align="char" char="." colspan="1" rowspan="1">14%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">68%</td><td align="left" colspan="1" rowspan="1">*Ascierto et&#160;al. 2016 [<xref rid="CIT0014" ref-type="bibr">14</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01689519">NCT01689519</ext-link></td><td align="left" colspan="1" rowspan="1">Vemurafenib</td><td align="char" char="." colspan="1" rowspan="1">17.4</td><td align="char" char="." colspan="1" rowspan="1">26%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">7.2</td><td align="char" char="." colspan="1" rowspan="1">10%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">50%</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">COLUMBUS</td><td align="left" colspan="1" rowspan="1">Encorafenib&#8201;+&#8201;Binimetinib</td><td align="char" char="." colspan="1" rowspan="1">33.6</td><td align="char" char="." colspan="1" rowspan="1">35%</td><td align="char" char="." colspan="1" rowspan="1">27.4%</td><td align="char" char="." colspan="1" rowspan="1">14.9</td><td align="char" char="." colspan="1" rowspan="1">23%</td><td align="char" char="." colspan="1" rowspan="1">21.2%</td><td align="char" char="." colspan="1" rowspan="1">64%</td><td rowspan="2" align="left" colspan="1">*Dummer et&#160;al. 2022 [<xref rid="CIT0018" ref-type="bibr">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01909453">NCT01909453</ext-link></td><td align="left" colspan="1" rowspan="1">Vemurafenib</td><td align="char" char="." colspan="1" rowspan="1">16.9</td><td align="char" char="." colspan="1" rowspan="1">21%</td><td align="char" char="." colspan="1" rowspan="1">18.2%</td><td align="char" char="." colspan="1" rowspan="1">7.3</td><td align="char" char="." colspan="1" rowspan="1">10%</td><td align="char" char="." colspan="1" rowspan="1">6.4%</td><td align="char" char="." colspan="1" rowspan="1">41%</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Encorafenib</td><td align="char" char="." colspan="1" rowspan="1">23.5</td><td align="char" char="." colspan="1" rowspan="1">35%</td><td align="char" char="." colspan="1" rowspan="1">31.7%</td><td align="char" char="." colspan="1" rowspan="1">9.6</td><td align="char" char="." colspan="1" rowspan="1">19%</td><td align="char" char="." colspan="1" rowspan="1">15.8%</td><td align="char" char="." colspan="1" rowspan="1">52%</td><td align="left" colspan="1" rowspan="1">**Schadendorff et&#160;al. 2024 [<xref rid="CIT0017" ref-type="bibr">17</xref>]</td></tr><tr><td rowspan="3" align="left" colspan="1">CheckMate067-Studie BRAF-mutated Subgroup; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01844505">NCT01844505</ext-link></td><td align="left" colspan="1" rowspan="1">Nivolumab&#8201;+&#8201;Ipilimumab</td><td align="left" colspan="1" rowspan="1">NR (50.7-NR)</td><td align="char" char="." colspan="1" rowspan="1">60%</td><td align="char" char="." colspan="1" rowspan="1">57%</td><td align="char" char="." colspan="1" rowspan="1">16.8</td><td align="char" char="." colspan="1" rowspan="1">38%</td><td align="char" char="." colspan="1" rowspan="1">38%</td><td align="left" colspan="1" rowspan="1">NR (21-NR)</td><td align="left" colspan="1" rowspan="1">*Larkin et&#160;al. 2019 [<xref rid="CIT0067" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nivolumab</td><td align="char" char="." colspan="1" rowspan="1">45.5</td><td align="char" char="." colspan="1" rowspan="1">46%</td><td align="char" char="." colspan="1" rowspan="1">43%</td><td align="char" char="." colspan="1" rowspan="1">5.6</td><td align="char" char="." colspan="1" rowspan="1">22%</td><td align="char" char="." colspan="1" rowspan="1">23%</td><td align="char" char="." colspan="1" rowspan="1">55 (20.6-NR)</td><td align="left" colspan="1" rowspan="1">**Wolchok et&#160;al. 2021 (only 6.5&#8201;years data) [<xref rid="CIT0033" ref-type="bibr">33</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ipilimumab</td><td align="char" char="." colspan="1" rowspan="1">24.6</td><td align="char" char="." colspan="1" rowspan="1">30%</td><td align="char" char="." colspan="1" rowspan="1">25%</td><td align="char" char="." colspan="1" rowspan="1">3.4</td><td align="char" char="." colspan="1" rowspan="1">11%</td><td align="char" char="." colspan="1" rowspan="1">9%</td><td align="char" char="." colspan="1" rowspan="1">14.4 (6.9-NR)</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Notably, comparisons between studies of BRAF inhibitors and immune checkpoint inhibitors are limited by the numerous differences in trial populations.</p></fn><fn id="TF2"><p>*Median 5&#8201;year data resources.</p></fn><fn id="TF3"><p>**Median 7&#8201;year data ressources.</p></fn><fn id="TF4"><p><italic toggle="yes">Abbreviations:</italic> n.a., data not available; NR, not reached; OS, overall survival, PFS, progression-free survival; ORR, overall response rate; IRC, independent review committee; mo, months.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2002"><label>3.2.</label><title>Patient 2: preexisting autoimmune diseases</title><p>Myasthenia gravis has been induced or exacerbated by ICI [<xref rid="CIT0020" ref-type="bibr">20&#8211;22</xref>,<xref rid="CIT0040" ref-type="bibr">40&#8211;43</xref>]. Preexisting autoimmune disease is not per se a contraindication against ICI therapy. However, data regarding patients with preexisting MG with melanoma treated with ICI are rare and based on small case series or cohorts [<xref rid="CIT0039" ref-type="bibr">39&#8211;42</xref>,<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref>]. Among patients with preexisting autoimmune disease who underwent ICI therapy, Huang [<xref rid="CIT0041" ref-type="bibr">41</xref>] documented 3 deaths out of 9 patients with preexisting MG, while another study observed four cases with MG and all developed immune-related toxicities and/or exacerbation of MG [<xref rid="CIT0049" ref-type="bibr">49</xref>].</p><p>On the other hand, the efficacy of ICI is maintained even in patients with underlying autoimmune diseases. For patients with persistent autoimmune diseases with advanced <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated melanomas, treatment decision should be taken based on a careful risk-benefit assessment and as an interdisciplinary shared decision [<xref rid="CIT0021" ref-type="bibr">21&#8211;23</xref>,<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0031" ref-type="bibr">31</xref>,<xref rid="CIT0043" ref-type="bibr">43</xref>]. As per prescription information, ICI as mono or combination therapy with IPI should not be started while the patient is receiving immunosuppressive agents like corticosteroids or other immunosuppressive therapies. Patients with a poor performance score &#8805;&#8201;2, active MBM or active autoimmune diseases, and patients who received systemic immunosuppressants before study entry were excluded from the pivotal clinical trials [<xref rid="CIT0020" ref-type="bibr">20&#8211;22</xref>].</p></sec><sec disp-level="2" id="S0003-S2003"><label>3.3.</label><title>Patient 3: aggressive course of the disease</title><p>In general, both treatment options, ICI and TT, can be offered to patients with <italic toggle="yes">BRAF</italic><sup>V600E/K</sup>- mutated melanoma stage IV. Systemic treatment strategies with high response rates combined with a short time to response are needed to use the window of opportunity for MBM treatment. Data regarding combination ICI [<xref rid="CIT0050" ref-type="bibr">50&#8211;56</xref>] and TT [<xref rid="CIT0057" ref-type="bibr">57&#8211;64</xref>] led to renewed considerations on how to plan the optimal treatment of MBM (<xref rid="t0002" ref-type="table">Table 2</xref>). However, the exemplary patient is not only suffering from symptomatic MBM, but he also suffers from a generally aggressive course of the disease associated with poor prognosis markers like high LDH and poor performance status (ECOG 1).</p><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Efficacy of targeted or checkpoint combination therapies in melanoma brain metastases (MBM) in BRAF-mutated melanoma.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Trial</th><th align="center" colspan="1" rowspan="1">Drugs</th><th align="center" colspan="1" rowspan="1">Cohorts</th><th align="center" colspan="1" rowspan="1">Median OS</th><th align="center" colspan="1" rowspan="1">Median PFS</th><th align="center" colspan="1" rowspan="1">Intracranial response (%) by investigators-icRR*</th><th align="center" colspan="1" rowspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">TRICOTEL</td><td align="left" colspan="1" rowspan="1">Cohort 1: Cobimetinib&#8201;+&#8201;Atezolizumab</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">BRAF</italic>-wt, MBM</td><td align="left" colspan="1" rowspan="1">--</td><td align="char" char="." colspan="1" rowspan="1">1.8&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03625141">NCT03625141</ext-link></td><td align="left" colspan="1" rowspan="1">Cohort 2: Vemurafenib&#8201;+&#8201;Cobimetinib&#8201;+&#8201;Atezolizumab</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">BRAF</italic> V600 mut. MBM</td><td align="char" char="." colspan="1" rowspan="1">13.4&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">5.5&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">Dummer, R et&#160;al. 2023 (58); Dummer R. et&#160;al 2024 [<xref rid="CIT0059" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Vemurafenib</td><td align="left" colspan="1" rowspan="1">Vemurafenib</td><td align="left" colspan="1" rowspan="1">C1: (previously untreated MBM)</td><td align="char" char="." colspan="1" rowspan="1">8.9&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">3.7&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">29</td><td rowspan="3" align="left" colspan="1">McArthur et&#160;al. 2017 [<xref rid="CIT0060" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">C2: (previously treated MBM)</td><td align="char" char="." colspan="1" rowspan="1">9.6&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">4&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">23</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01378975">NCT01378975</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">C1 &amp; C2</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">27</td></tr><tr><td align="left" colspan="1" rowspan="1">Break-MB</td><td align="left" colspan="1" rowspan="1">Dabrafenib</td><td align="left" colspan="1" rowspan="1">A(prior locally untreated MBM)</td><td align="char" char="." colspan="1" rowspan="1">6.8&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">16.1&#8201;weeks</td><td align="char" char="." colspan="1" rowspan="1">40.5</td><td align="left" colspan="1" rowspan="1">Long et&#160;al 2012 [<xref rid="CIT0061" ref-type="bibr">61</xref>]; Kirkwood et&#160;al. 2012 [<xref rid="CIT0062" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">Dabrafenib</td><td align="left" colspan="1" rowspan="1">B (prior locally treated MBM)</td><td align="char" char="." colspan="1" rowspan="1">7.6&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">16.0&#8201;weeks</td><td align="char" char="." colspan="1" rowspan="1">36.9</td><td rowspan="2" align="left" colspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT01266967">NCT01266967</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">COMBI-MB</td><td align="left" colspan="1" rowspan="1">Dabrafenib&#8201;+&#8201;Trametinib</td><td align="left" colspan="1" rowspan="1">A (<italic toggle="yes">BRAF</italic> V600E mut., asymptomatic, locally untreated MBM)</td><td align="char" char="." colspan="1" rowspan="1">10.8&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">5.6&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">58</td><td rowspan="4" align="left" colspan="1">Davies et&#160;al. 2017 [<xref rid="CIT0063" ref-type="bibr">63</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1">Dabrafenib&#8201;+&#8201;Trametinib</td><td align="left" colspan="1" rowspan="1">B (<italic toggle="yes">BRAF</italic> V600E mut, asymptomatic, locally pretreated MBM)</td><td align="char" char="." colspan="1" rowspan="1">24.3&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">7.2&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">56</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02039947">NCT02039947</ext-link></td><td align="left" colspan="1" rowspan="1">Dabrafenib&#8201;+&#8201;Trametinib</td><td align="left" colspan="1" rowspan="1">C (<italic toggle="yes">BRAF</italic> V600D/E/K/R mut, asymptomatic, locally pretreated or untreated MBM)</td><td align="char" char="." colspan="1" rowspan="1">10.1&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">4.2&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">44</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Dabrafenib&#8201;+&#8201;Trametinib</td><td align="left" colspan="1" rowspan="1">D (<italic toggle="yes">BRAF</italic> V600D/E/K/R mut, symptomatic, locally pretreated or untreated MBM)</td><td align="char" char="." colspan="1" rowspan="1">11.5&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">5.5&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">59</td></tr><tr><td align="left" colspan="1" rowspan="1">GEM1802/E-BRAIN</td><td align="left" colspan="1" rowspan="1">Encorafenib&#8201;+&#8201;Binimetinib</td><td align="left" colspan="1" rowspan="1">All: <italic toggle="yes">BRAF</italic> V600 mut.positive, C1 &amp; C2 MBM</td><td align="char" char="." colspan="1" rowspan="1">15.9&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">7.7&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">70.8</td><td rowspan="3" align="left" colspan="1">Marquez-Rodas et&#160;al. 2024 [<xref rid="CIT0064" ref-type="bibr">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">Encorafenib&#8201;+&#8201;Binimetinib</td><td align="left" colspan="1" rowspan="1">C1 (untreated asymptomatic MBM)</td><td align="char" char="." colspan="1" rowspan="1">13.9&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">8.3&#8201;mo (IC); 7.4&#8201;mo (EC)</td><td align="char" char="." colspan="1" rowspan="1">80</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03898908">NCT03898908</ext-link></td><td align="left" colspan="1" rowspan="1">Encorafenib&#8201;+&#8201;Binimetinib</td><td align="left" colspan="1" rowspan="1">C2 (untreated symptomatic MBM)</td><td align="char" char="." colspan="1" rowspan="1">16.1&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">8.7&#8201;mo (IC); 8.7&#8201;mo (EC)</td><td align="char" char="." colspan="1" rowspan="1">61</td></tr><tr><td align="left" colspan="1" rowspan="1">CheckMate-204</td><td align="left" colspan="1" rowspan="1">Nivolumab&#8201;+&#8201;Ipilimumab--&gt; Nivolumab</td><td align="left" colspan="1" rowspan="1">A: asymptomatic, corticosteroid-untreated MBM</td><td align="char" char="." colspan="1" rowspan="1">45.8&#8201;mo (upper limit of CI not reached)</td><td align="char" char="." colspan="1" rowspan="1">29.54&#8201;mo (upper limit of CI not reached)</td><td align="char" char="." colspan="1" rowspan="1">53.5</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">(A-Subgroupanalysis of <italic toggle="yes">BRAF</italic> mut pts - <bold>65%</bold> of all pts)</td><td align="char" char="." colspan="1" rowspan="1">3 years OS rate: 73%</td><td align="left" colspan="1" rowspan="1">n.a</td><td align="left" colspan="1" rowspan="1">n.a.</td><td rowspan="2" align="left" colspan="1">Tawbi et&#160;al. 2021 [<xref rid="CIT0052" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02320058">NCT02320058</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">B: symptomatic and/or corticosteroid-treated MBM</td><td align="char" char="." colspan="1" rowspan="1">8.8&#8201;mo (upper limit of CI not reached)</td><td align="char" char="." colspan="1" rowspan="1">1.2&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">16.7</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">B-no subgroup analysis due to few pts (n&#8201;=&#8201;18), 8 pts <bold>(44%)</bold>
<italic toggle="yes">BRAF</italic> mut</td><td align="left" colspan="1" rowspan="1">n.a</td><td align="left" colspan="1" rowspan="1">n.a</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="left" colspan="1" rowspan="1">Tawbi et&#160;al. 2021 [<xref rid="CIT0053" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ABC Study</td><td align="left" colspan="1" rowspan="1">Nivolumab&#8201;+&#8201;Ipilimumab</td><td align="left" colspan="1" rowspan="1">A: untreated asymptomatic MBM</td><td align="char" char="." colspan="1" rowspan="1">51% (5 years OS rate)</td><td align="char" char="." colspan="1" rowspan="1">46% (5 years, IC PFS)</td><td align="char" char="." colspan="1" rowspan="1">51</td><td rowspan="3" align="left" colspan="1">Long et&#160;al. 2021 [<xref rid="CIT0051" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">Nivolumab</td><td align="left" colspan="1" rowspan="1">B: untreated asymptomatic MBM</td><td align="char" char="." colspan="1" rowspan="1">34% (5 years OS rate)</td><td align="char" char="." colspan="1" rowspan="1">15% (5 years IC PFS)</td><td align="char" char="." colspan="1" rowspan="1">20</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02374242">NCT02374242</ext-link></td><td align="left" colspan="1" rowspan="1">Nivolumab</td><td align="left" colspan="1" rowspan="1">C: locally pretreated symptomatic MBM</td><td align="char" char="." colspan="1" rowspan="1">13% (5 years OS rate)</td><td align="char" char="." colspan="1" rowspan="1">6% (5 years IC PFS)</td><td align="char" char="." colspan="1" rowspan="1">6</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">NIBIT-M2</td><td align="left" colspan="1" rowspan="1">A: Fotemustine</td><td align="left" colspan="1" rowspan="1">asymtomatic MBM (35%*)</td><td align="char" char="." colspan="1" rowspan="1">8.5&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">3&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">Di Giacomo et&#160;al. 2024 [<xref rid="CIT0054" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1">B: Ipilimumab&#8201;+&#8201;Fotemustine</td><td align="left" colspan="1" rowspan="1">asymtomatic MBM (42%*)</td><td align="char" char="." colspan="1" rowspan="1">8.2&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">3.3&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">19.2</td><td rowspan="2" align="left" colspan="1">Di Giacomo et&#160;al. 2021 [<xref rid="CIT0055" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02460068">NCT02460068</ext-link></td><td align="left" colspan="1" rowspan="1">C: Ipilimumab&#8201;+&#8201;Nivolumab</td><td align="left" colspan="1" rowspan="1">asymtomatic MBM (41%*)</td><td align="char" char="." colspan="1" rowspan="1">29.2&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">8.7&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">44.4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Pembrolizumab</td><td align="left" colspan="1" rowspan="1">asymtomatic MBM (41%*)</td><td align="char" char="." colspan="1" rowspan="1">17&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">2&#8201;mo</td><td align="char" char="." colspan="1" rowspan="1">26</td><td rowspan="3" align="left" colspan="1">Kluger et&#160;al. 2019 [<xref rid="CIT0056" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02085070">NCT02085070</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn id="TF5"><p>*BRAF V600-mutated patients.</p></fn><fn id="TF6"><p><italic toggle="yes">Abbreviations:</italic> MBM, melanoma brain metastases; EC, extracranial; OS, overall survival; IC, intercranial; n.a., not available; PFS, progression-free survival; ORR, overall response rate; icRR, intercranial response rate; mo, months.</p></fn></table-wrap-foot></table-wrap><p>Immunotherapy can show a delayed onset of treatment action, inducing delayed tumor responses even after an initial increase in the size of the metastases [<xref rid="CIT0021" ref-type="bibr">21&#8211;23</xref>,<xref rid="CIT0030" ref-type="bibr">30</xref>]. These new kinetics of responses were incorporated in the iRECIST (immune RECIST) evaluation system, replacing, for these therapies, the usual standard radiologic evaluation criteria (RECIST-1.1) [<xref rid="CIT0065" ref-type="bibr">65</xref>]. This should be considered before initiating treatment in patients with rapidly progressing disease. The ESMO Guidelines 2022 [<xref rid="CIT0036" ref-type="bibr">36</xref>] recommend considering TT as an alternative to ICI for first-line treatment of <italic toggle="yes">BRAF</italic>-mutated melanoma in specific scenarios, such as poor performance status, high lactate dehydrogenase (LDH) levels, high tumor burden, an aggressive disease course, symptomatic MBM, and/or patient preference. The recently published ESMO 2024 guidelines recommend either ICI or TT as the standard of care (SoC) treatment options for <italic toggle="yes">BRAF</italic>-mutated patients in the first-line setting, although ICI remain the preferred option, i.e., when no rapid response is required due to aggressive/symptomatic disease [<xref rid="CIT0030" ref-type="bibr">30</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref>].</p><p>Although the treatment landscape for MBM is rapidly evolving, there is still room for further evolution as treatment success for symptomatic MBM is still limited. New systemic therapies contribute additional value to the standard approaches for MBM, such as neurosurgical resection of lesions and radiotherapy (WBRT or SRS). Systemic treatments like ICI and TT have proven effective in targeting MBM (<xref rid="t0002" ref-type="table">Table 2</xref>). However, effectiveness varies according to the presence of symptoms of the MBM. While an intracranial response rate (icRR) and long-term benefit were seen in asymptomatic patients, the icRR rate was reduced to 6% in symptomatic patients (<xref rid="t0002" ref-type="table">Table 2</xref>). Additionally, the definition of asymptomatic and symptomatic MBM remains heterogeneous and differs from one treating physician to another [<xref rid="CIT0038" ref-type="bibr">38</xref>]. This is why study results need to be interpreted carefully.</p><p>The standard of care for asymptomatic MBM is ICI as first-line therapy [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Current ESMO guidelines recommend alternatively TT with BRAF/MEK inhibitors for <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated metastatic melanoma with symptomatic MBM [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Targeted combination therapy is effective in symptomatic MBM and shows high icRR of 59% for the dabrafenib-trametinib combination up to 61% with EB (<xref rid="t0002" ref-type="table">Table 2</xref>) [<xref rid="CIT0063" ref-type="bibr">63</xref>,<xref rid="CIT0064" ref-type="bibr">64</xref>]. The OS rates and PFS rates remain low underlining the need for rapid and durable responses in symptomatic MBM.</p><p>Probable causes of shortened duration of response in the brain are diverse, including the microenvironment in and poor drug penetration into the brain as well as probably incomplete MAPK pathway inhibition. Results of the phase II GEM1802/E-BRAIN trial (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03898908">NCT03898908</ext-link>) investigating EB treatment effects before local treatment in patients with <italic toggle="yes">BRAF</italic>&#226;&#177;&#189;<sup>600</sup>-mutated MBM showed an icRR before radiosurgery to EB in 80% of asymptomatic (C1) and 61% of symptomatic (C2) MBM [<xref rid="CIT0064" ref-type="bibr">64</xref>,<xref rid="CIT0066" ref-type="bibr">66</xref>]. Encorafenib and binimetinib achieve a significant icRR in patients with symptomatic <italic toggle="yes">BRAF</italic>-mutated MBM and poor prognostic factors (need for steroids and high intracranial tumor burden). Brain radiotherapy is feasible and could help improve the intracranial disease control provided by EB [<xref rid="CIT0064" ref-type="bibr">64</xref>]. However, patients with MBM need interdisciplinary care and multidisciplinary decision-making based on, e.g., the number of MBMs, location, size and extension of extracranial disease. The ESMO Guidelines 2024 [<xref rid="CIT0030" ref-type="bibr">30</xref>] suggest considering neurosurgery, SRS, TT with a BRAF inhibitor (BRAFi)&#8211;MEK inhibitor (MEKi) combination, and ICI for MBM. Although it has not been determined yet whether there is an optimal sequence or combination of local and systemic therapies. Therefore, only recent study results can assist in decision-making for now until ongoing clinical trials provide more definitive answers [<xref rid="CIT0030" ref-type="bibr">30</xref>].</p></sec></sec><sec disp-level="1" id="S0004"><label>4.</label><title>Discussion: novel treatment approaches, such as sandwich therapy</title><p>Both ICI and TT allow for the tailoring of treatment to patients&#8217; characteristics, medical history, and comorbidities. Additionally, the different safety profiles might play a role in treatment selection, as shown in the second case. Other important factors for treatment decisions are specific circumstances, e.g., high tumor burden, rapidly progressing disease, and high LDH (as shown in the third case). For these patients, fast and durable responses are required. While the onset of clinical response is generally fast in TT, the onset of therapeutic action of ICI might be rather slow. On the other hand, higher duration and deepness of responses have been shown with ICI [<xref rid="CIT0067" ref-type="bibr">67</xref>,<xref rid="CIT0068" ref-type="bibr">68</xref>] Rapid responses seen with TT and modulation of the tumor microenvironment may open a window of opportunity for an early switch to ICI, combining both fast and long-lasting deep responses [<xref rid="CIT0069" ref-type="bibr">69</xref>,<xref rid="CIT0070" ref-type="bibr">70</xref>].</p><p>New concepts of switching from TT to ICI before progression have been developed based on reports that TT transiently increases tumor antigen presentation and tumor influx of T cells [<xref rid="CIT0071" ref-type="bibr">71</xref>]. This rationale is also based on the idea that when prompt and reliable responses to TT are desired, an early switch from TT to ICI might prevent tumor cells from acquiring cross-resistance to ICI [<xref rid="CIT0072" ref-type="bibr">72</xref>].</p><p>The ESMO 2024 guidelines outline first-line treatment choices between TT and ICI, based on various prospective trials, to determine the optimal sequencing strategy [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Four trials investigating the best treatment sequence were recently published: one phase III trial (DREAMseq) [<xref rid="CIT0073" ref-type="bibr">73</xref>] and three phase II clinical trials (SECOMBIT [<xref rid="CIT0074" ref-type="bibr">74</xref>,<xref rid="CIT0075" ref-type="bibr">75</xref>], EBIN [<xref rid="CIT0076" ref-type="bibr">76</xref>], ImmunoCobiVem [<xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>]) (<xref rid="t0003" ref-type="table">Table 3</xref>). The phase III randomized trial addressing the sequencing problem is DREAMSeq (doublet, randomized evaluation in advanced melanoma sequencing) study recently published [<xref rid="CIT0072" ref-type="bibr">72</xref>]. Results from the DREAMSeq investigated how patients with <italic toggle="yes">BRAF</italic>-mutant melanoma could take advantage of both ICI and TT when starting their treatment with TT combining DT followed by ICI combination IPI and N, or vice versa. The study found that patients treated with N and IPI followed by DT at disease progression experienced a greater 2-year OS rate (72%) compared with patients receiving the reverse sequence (52%). In fact, because of the substantial differences between the two groups, the trial&#8217;s oversight committee halted the trial early. Data for EB sequencing was collected in the SECOMBIT and EBIN phase II trials investigating the sequencing of ipilimumab plus nivolumab and EB for untreated <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutated metastatic melanoma [<xref rid="CIT0074" ref-type="bibr">74&#8211;76</xref>]. Patients in SECOMBIT trial were randomized to one of two sequences with TT encorafenib and binimetinib (A, combo T) or ICI (B, combo I) first followed by ICI or EB upon progression or to a third arm in which an 8-week induction course of EB followed by a planned switch to ICI as the first treatment followed by EB upon progression (C, sandwich). The results of DREAMSeq were confirmed by SECOMBIT phase II trial, while arm C with 8&#8201;weeks EB induction showed even greater benefit (<xref rid="t0003" ref-type="table">Table 3</xref>). At 60&#8201;months, the brain metastases free survival (BMFS) was 85% in sandwich arm, 80% in combo I, and only 56% in combo T arm. In the subgroup analysis, patients with elevated LDH or with &gt;3 metastatic sites showed a better trend regarding total PFS and OS in combo I and sandwich arm. With a median follow-up of 56&#8201;months (IQR: 48&#8211;63) 5-year rate of both total PFS and OS confirmed a better trend for arms B and C [<xref rid="CIT0074" ref-type="bibr">74</xref>]. In summary, SECOMBIT results show a clinical benefit in three different sequencing schemas for EB and ICI in treating <italic toggle="yes">BRAF</italic><sup>V600</sup>-mutant melanoma, with survival and safety outcomes consistent with the results of other studies.</p><table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>Ongoing clinical trials exploring the sequencing of combination targeted and immune therapies in advanced BRAF-mutated melanoma discussed in the text.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Trial</th><th align="center" colspan="1" rowspan="1">Drugs</th><th align="center" colspan="1" rowspan="1">Cohorts</th><th align="center" colspan="1" rowspan="1">2 years OS rate %</th><th align="center" colspan="1" rowspan="1">3 years OS rate</th><th align="center" colspan="1" rowspan="1">Median PFS mo</th><th align="center" colspan="1" rowspan="1">2 years PFS rate</th><th align="center" colspan="1" rowspan="1">ORR</th><th align="center" colspan="1" rowspan="1">DOR</th><th align="center" colspan="1" rowspan="1">Reference</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">DREAMSeq</td><td align="left" colspan="1" rowspan="1">nivolumab/ Ipilimumab, dabrafenib/ trametinib</td><td align="left" colspan="1" rowspan="1">Arm A: ipilimumab&#8201;+&#8201;nivolumab q3w x2 induction followed by nivolumab until 84&#8201;weeks or 72&#8201;weeks of maintenance therapy --&gt; PD --&gt; ARM C: dabrafenib&#8201;+&#8201;tramentinib</td><td align="char" char="." colspan="1" rowspan="1">71.8%</td><td align="left" colspan="1" rowspan="1">c</td><td align="left" colspan="1" rowspan="1">A: 11.8&#8201;C: 9.9</td><td align="char" char="." colspan="1" rowspan="1">41.9%</td><td align="left" colspan="1" rowspan="1">A:46.0% C: 47.85%</td><td align="char" char="." colspan="1" rowspan="1">&gt;29&#8201;mo</td><td align="left" colspan="1" rowspan="1">Atkins et&#160;al. 2023 [<xref rid="CIT0073" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Arm B: dabrafenib&#8201;+&#8201;trametinib --&gt;PD --&gt; Arm D: ipilimumab&#8201;+&#8201;nivolumab q3w x2 induction followed by nivolumab until 84&#8201;weeks or 72&#8201;weeks of maintenance therapy</td><td align="char" char="." colspan="1" rowspan="1">51.5%</td><td align="char" char="." colspan="1" rowspan="1">42.80%</td><td align="left" colspan="1" rowspan="1">B: 8.5&#8201;D: 2.9</td><td align="char" char="." colspan="1" rowspan="1">19.2%</td><td align="left" colspan="1" rowspan="1">B: 43.0% D: 29.6%</td><td align="char" char="." colspan="1" rowspan="1">12.7&#8201;mo</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02224781">NCT02224781</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">SECOMBIT</td><td align="left" colspan="1" rowspan="1">nivolumab/ ipilimumab, encorafenib/ binimetinib</td><td align="left" colspan="1" rowspan="1">Cobmo T (Arm A): encorafenib [450&#8201;mg QD]/binimetinib [45&#8201;mg BID] --&gt; PD--&gt; ipilimumab [3&#8201;mg/kg] + nivolumab [1&#8201;mg/kg] q3w x 4 followed by nivolumab [3&#8201;mg/kg] q2w maintenance therapy until progression</td><td align="char" char="." colspan="1" rowspan="1">65.0%</td><td align="char" char="." colspan="1" rowspan="1">54%</td><td align="char" char="." colspan="1" rowspan="1">&#8764;7.4</td><td align="char" char="." colspan="1" rowspan="1">46.0%</td><td align="left" colspan="1" rowspan="1">A1:87%, A*:25.7%</td><td align="left" colspan="1" rowspan="1">n-a.</td><td align="left" colspan="1" rowspan="1">Ascierto et&#160;al. 2024 [<xref rid="CIT0074" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Combo I (Arm B): ipilimumab [3&#8201;mg/kg] + nivolumab [1&#8201;mg/kg] q3w x 4 followed by nivolumab [3&#8201;mg/kg] q2w maintenance therapy --&gt; PD--&gt; encorafenib [450&#8201;mg QD]/binimetinib [45&#8201;mg BID] until progression</td><td align="char" char="." colspan="1" rowspan="1">73.0%</td><td align="char" char="." colspan="1" rowspan="1">62%</td><td align="char" char="." colspan="1" rowspan="1">&#8764;16.3</td><td align="char" char="." colspan="1" rowspan="1">65.0%</td><td align="left" colspan="1" rowspan="1">B1: 44.9% B*:57.9%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="left" colspan="1" rowspan="1">Ascierto et&#160;al. 2023 [<xref rid="CIT0075" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02631447">NCT02631447</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Sandwich/Switch (Arm C): encorafenib [450&#8201;mg QD]/binimetinib [45&#8201;mg BID] for 8&#8201;week induction --&gt; switch without progression to: ipilimumab [3&#8201;mg/kg] + nivolumab [1&#8201;mg/kg] q3w x 4 followed by nivolumab [3&#8201;mg/kg] q2w maintenance therapy--&gt; PD --&gt; encorafenib [450&#8201;mg QD] /binimetinib [45&#8201;mg BID]</td><td align="char" char="." colspan="1" rowspan="1">69.0%</td><td align="char" char="." colspan="1" rowspan="1">60%</td><td align="char" char="." colspan="1" rowspan="1">&#8764;12.1</td><td align="char" char="." colspan="1" rowspan="1">57.0%</td><td align="left" colspan="1" rowspan="1">C:82.4% C*: 62.2%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">EBIN</td><td align="left" colspan="1" rowspan="1">nivolumab/ipilimumab</td><td align="left" colspan="1" rowspan="1">Arm A: ICI: nivo [3&#8201;mg/kg] + ipi [1&#8201;mg/kg] q3w x4 --&gt; nivo [480&#8201;mg] iv q4w --&gt; PD</td><td align="char" char="." colspan="1" rowspan="1">74.0%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">9</td><td align="char" char="." colspan="1" rowspan="1">35.0%</td><td align="char" char="." colspan="1" rowspan="1">45%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="left" colspan="1" rowspan="1">Robert et&#160;al. 2024 [<xref rid="CIT0076" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">encorafenib/binimetinib --&gt; nivolumab&#8201;+&#8201;ipilimumab</td><td align="left" colspan="1" rowspan="1">Arm B: sequence; 3&#8201;mo induction with encorafenib [450&#8201;mg QD]/binimetinib [45&#8201;mg BID] orally, 1 week break --&gt; nivo [3&#8201;mg/kg] + ipi [1&#8201;mg/kg] q3w x4 --&gt; by nivo [480&#8201;mg] iv q4w --&gt; PD</td><td align="char" char="." colspan="1" rowspan="1">68.0%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="char" char="." colspan="1" rowspan="1">9</td><td align="char" char="." colspan="1" rowspan="1">29.0%</td><td align="char" char="." colspan="1" rowspan="1">53%</td><td align="left" colspan="1" rowspan="1">n.a.</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03235245">NCT03235245</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">ImmunoCobiVem</td><td align="left" colspan="1" rowspan="1">vemurafenib /cobimetinib (VC) --&gt; atezolizumab**</td><td align="left" colspan="1" rowspan="1">Arm A: vemurafenib[960&#8201;mg BID; 28/0] /cobimetinib[60&#8201;mg QD, 21/7] for 3&#8201;mo--&gt;no PD/no unaccept. toxicity/no treatment interruption. --&gt; proceed with VC --&gt; PD --&gt; atezolizumab** [1200&#8201;mg iv q3w]</td><td align="char" char="." colspan="1" rowspan="1">58.0%</td><td align="char" char="." colspan="1" rowspan="1">55%</td><td align="char" char="." colspan="1" rowspan="1">13</td><td align="char" char="." colspan="1" rowspan="1">29.0%</td><td align="char" char="." colspan="1" rowspan="1">74% (5%<sup>+</sup>)</td><td align="char" char="." colspan="1" rowspan="1">12&#8201;mo</td><td rowspan="2" align="left" colspan="1">Schadendorf et&#160;al. 2024 [<xref rid="CIT0077" ref-type="bibr">77</xref>]; Livingstone et&#160;al 2023 [<xref rid="CIT0078" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phase II</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">Arm B (early switch after run in phase): vemurafenib[960&#8201;mg BID; 28/0] /cobimetinib[60&#8201;mg QD, 21/7] for 3&#8201;mo --&gt; no PD/no unacc. toxicity/no treatment interruption. --&gt; atezolizumab** [1200&#8201;mg iv q3w]</td><td align="char" char="." colspan="1" rowspan="1">68.0%</td><td align="char" char="." colspan="1" rowspan="1">55%</td><td align="char" char="." colspan="1" rowspan="1">5.9</td><td align="char" char="." colspan="1" rowspan="1">19.0%</td><td align="char" char="." colspan="1" rowspan="1">74% (40%<sup>+</sup>)</td><td align="char" char="." colspan="1" rowspan="1">3&#8201;mo</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02902029">NCT02902029</ext-link></td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn id="TF7"><p>*Post progression treatment.</p></fn><fn id="TF8"><p>**Not approved for melanoma treatment.</p></fn><fn id="TF9"><p><sup>+</sup>Post cross-over.</p></fn><fn id="TF10"><p><italic toggle="yes">Abbreviations:</italic> DOR, duration of response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; ORR, overall response rate; icRR, intercranial response rate; mo, months; 21/7, cobimetinib is given a 28-day cycle, each dose taken QD for 21 consecutive days followed by a 7-day break; n.a., not available.</p></fn></table-wrap-foot></table-wrap><p>Latest research results on induction treatment with EB before a combined ICI with ipilimumab&#8201;+&#8201;nivolumab in patients with advanced <italic toggle="yes">BRAF</italic><sup>V600E/K</sup>-mutant melanoma, were presented at ASCO Annual Meeting 2024 [<xref rid="CIT0076" ref-type="bibr">76</xref>]. As in SECOMBIT Arm C, the EORTC EBIN phase II trial included a preplanned switch from EB to ICI. The international randomized controlled phase II EBIN EORTC trial comparing upfront ICI followed by EB (arm A) with the sequential sandwich approach (arm B: 3&#8201;months induction EB, followed by 1-week therapy break and then ICI) failed to demonstrate the superiority of arm B in PFS and OS. Currently, the different duration of induction therapy (8&#8201;weeks in SECOMBIT vs. 12&#8201;weeks in EBIN), is guided by predefined time schedules. One approach discussed to guide the timing of the run-in phase in a personalized manner is the early analysis of circulating tumor DNA (ctDNA) levels [<xref rid="CIT0079" ref-type="bibr">79</xref>]. However the nivolumab dosing differed in the switching arms within SECOMBIT (IPI [3&#8201;mg/kg] + N [1&#8201;mg/kg] q3w x 4 followed by N [3&#8201;mg/kg] q2w maintenance therapy) compared to EBIN (N [3&#8201;mg/kg] + IPI [1&#8201;mg/kg] q3w x4 followed after a pause of 1 week by N [480&#8201;mg] iv q4w). A post-hoc subgroup analysis of EBIN supports the hypothesis that patients with very high LDH (2 &#8805;ULN) and those with liver metastases could benefit from the induction approach. Currently, the best timepoint for switching and the best dosing of ICI is unknown. Switching in the metastatic setting in the absence of progression carries the risk of discontinuing an effective treatment in favor of another treatment with potentially lower efficacy. ImmunoCobiVem trial [<xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref>] showed no significant benefit in 2-year and 3-year-OS rate for VC until progression followed by atezolizumab vs. 3&#8201;months run-in phase with VC followed by atezolizumab. Current studies show differences but are hypotheses generating due to the phase II study design and small study populations. Therefore, confirmatory phase III clinical trials are needed to address open questions. Additionally, new questions need to be addressed based on the guidelines recommendation for the adjuvant setting as patients will increasingly be pretreated with ICI or TT as standard of care [<xref rid="CIT0030" ref-type="bibr">30</xref>] which was not the case during recruitment of DREAMSeq, SECOMBIT, EBIN and ImmunoCobiVem studies [<xref rid="CIT0080" ref-type="bibr">80</xref>]. Therefore ESMO guidelines for 2024 emphasize the need for prospective data on the best treatment strategies for patients with unresectable stage III or IV melanoma who have previously received adjuvant therapy [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Research is ongoing.</p><p>Despite the need for more data, ESMO 2024 guidelines recommend TT for 8&#8211;12&#8201;weeks followed by ipilimumab&#8211;nivolumab (as per SECOMBIT arm C or EBIN arm B) as an option, especially for patients with high LDH levels and/or liver metastases, although induction TT is not EMA or FDA approved [<xref rid="CIT0030" ref-type="bibr">30</xref>].</p><p>Clinical experience shows that rapid disease progression and poor performance status after first-line treatment could significantly reduce the proportion of patients receiving a second-line therapy.</p><p>In metastatic melanoma with brain metastases, the combination of stereotactic radiosurgery and systemic therapy represents the current standard for durable intracranial control in patients with symptomatic disease. A recent systematic review of current treatment modalities for MBM based on 70 studies [<xref rid="CIT0081" ref-type="bibr">81</xref>] and a review regarding local treatment approaches [<xref rid="CIT0082" ref-type="bibr">82</xref>] underline that approaches are shifting toward multimodal strategies that integrate or sequence local and different systemic therapies. Interdigitating SRS with ICI therapy&#8212;ideally concomitant or early in the course of ICI (but not before the start of ICI)&#8212;offers the best synergy and clinical outcomes [<xref rid="CIT0081" ref-type="bibr">81</xref>,<xref rid="CIT0083" ref-type="bibr">83</xref>].</p><p>Neurosurgery retains a critical role in symptomatic or the few diagnostically uncertain cases. Multidisciplinary decision-making tailored to lesion number, symptomatology, steroid use, and extracranial disease status is essential for optimal patient outcomes. Ongoing trials such as SWOG S2001 (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04511013">NCT04511013</ext-link> [<xref rid="CIT0084" ref-type="bibr">84</xref>] and ABC-X (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03340129">NCT03340129</ext-link> [<xref rid="CIT0085" ref-type="bibr">85</xref>]) are evaluating the optimal sequencing of SRS and ICI. Prospective, biomarker-driven research is essential to clarify treatment sequences, optimize intracranial control, and enhance QoL. Multimodal approaches will shape the future standard of care.</p></sec><sec sec-type="conclusions" disp-level="1" id="S0005"><label>5.</label><title>Conclusions</title><p>Our clinical practice experience highlights the importance of personalized treatments in patients with <italic toggle="yes">BRAF</italic>
<sup>V600</sup>-mutated, advanced melanoma. Depending on the disease and patient characteristics, both ICI and TT provide valid therapeutic options.</p><p>The COLUMBUS trial has established BRAF/MEK inhibition with encorafenib&#8201;+&#8201;binimetinib as a highly effective first-line option in V600-mutant melanoma. Sequencing trials such as SECOMBIT and DREAMSeq have addressed sequencing of ICI vs. TT in <italic toggle="yes">BRAF</italic><sup>V600E/K</sup>/<sup>K</sup> -mutant patients. They demonstrated an advantage for patients starting on ICI vs. BRAF/MEK inhibition. Future strategies should leverage biomarkers, brain/liver metastasis-directed therapy, and clinical phenotypes to personalize sequencing decisions.</p><p>BRAF non-V600 mutations (e.g., D594, K601E) do not respond to current BRAF inhibitors and should be treated with ICI if there are no clinical trial options such as exarafenib.</p><p>In 2024, many patients presenting with a new diagnosis of advanced melanoma have progressed on or soon after receiving adjuvant systemic therapy with either ICI or TT. It remains unclear whether the results of the DREAMseq phase III and the phase II SECOMBIT, EBIN and ImmunoCobiVem trials apply in this setting and how adjuvant therapies affect the tumor microenvironment. Additionally, SECOMBIT and EBIN phase II trials showed differences in the study design. The duration of induction therapy differed regarding timelines (8&#8201;weeks in SECOMBIT vs. 12&#8201;weeks with a 1-week pause before ICI start in EBIN and ImmunoCobiVem trial) and dosing of nivolumab as maintenance therapy was 3&#8201;mg/kg q2w and 480&#8201;mg q4w, respectively. There is no clear recommendation on how to guide timing of switching. Approaches under discussion are, e.g., early ctDNA-guided personalized timing of the run-in phase in stage IV melanoma. The strategy of transitioning therapy before radiologic progression in metastatic melanoma is biologically and clinically plausible, especially to preempt resistance and preserve long-term immunologic control. Data from SECOMBIT (Arm C) support this rationale. However, to justify this approach beyond empiricism, the integration of quantitative, predictive biomarkers, such as ctDNA and immune activity profiles, is essential. Prospective validation is the next critical step by a prospective, ctDNA-guided switch trial.</p></sec><sec disp-level="1" id="S0006"><label>6.</label><title>Future perspectives</title><p>Prospective biomarker-guided clinical trials are needed to define the best treatment sequence for specific patients with their individual medical history, characteristics, mutation patterns and individualized treatment objectives. The most promising biomarkers from the authors point of view include ctDNA (for early response monitoring, minimal residual disease, and adaptive therapy) [<xref rid="CIT0079" ref-type="bibr">79</xref>,<xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref>]; gene and protein expression signatures such as interferon-gamma signature (IGS) [<xref rid="CIT0088" ref-type="bibr">88</xref>], MERLIN [<xref rid="CIT0089" ref-type="bibr">89</xref>], commercial or investigational assays like immunoprint<sup>&#174;</sup> [<xref rid="CIT0090" ref-type="bibr">90</xref>] and MelaGenix [<xref rid="CIT0091" ref-type="bibr">91</xref>] (for predictive modeling), and tumor-infiltrating lymphocyte (TIL) [<xref rid="CIT0092" ref-type="bibr">92</xref>] density and composition (for mechanistic insights into immune engagement and tumor microenvironment). Tumor mutational burden (TMB<bold>)</bold> and PD-L1 expression have limited melanoma-specific predictive value but remain relevant in multi-cancer platforms.</p><p>Future directions should adopt multi-omic, longitudinal biomarker strategies with integrated translational endpoints to personalize therapy and explore mechanisms of resistance in metastatic melanoma through prospective, biomarker-guided interventional trials&#8212;particularly ctDNA-informed designs. Ideally, this would involve combining liquid biopsy with tissue-based immune profiling in precision immuno-oncology trials.</p><p>Looking ahead, the treatment landscape of metastatic melanoma is poised for a paradigm shift driven by more precise, biomarker-guided approaches. Over the next 5 to 10&#8201;years, we anticipate a transition from one-size-fits-all TT or ICI to adaptive treatment strategies that incorporate real-time biomarkers such as ctDNA, gene or protein expression signatures, spatial immune profiling, and T cell receptor (TCR) clonality. These tools will help detect responders and non-responders early, even before treatment starts, guiding adaptive therapy sequencing or escalation before clinical progression. Innovative therapeutic platforms&#8212;such as personalized neoantigen vaccines, off-the-shelf TCR or TIL cell therapies, and strategic ICI combinations targeting resistance pathways&#8212;are expected to broaden treatment options, especially for patients with primary or acquired resistance to checkpoint blockade. Ultimately, the convergence of ICI, TT, systems biology, and artificial intelligence will usher in a new era of truly personalized melanoma care, where molecular evolution, immune dynamics, and individual patient biology increasingly inform treatment decisions.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors received editorial support in preparing this report from Dipl.-Biol. Dipl.-Ing. Lydia Budiner, funded by Pierre Fabre Pharma Germany. However, the authors directed and are fully responsible for this manuscript&#8217;s content and editorial decisions.</p></ack><sec disp-level="1" id="S0010"><title>Ethical approval</title><p>N.a. this was a retrospective case documentation with patients treated with approved and appropriate drugs.</p></sec><sec disp-level="1" id="S0009"><title>Ethical declaration</title><p>The patients in this manuscript have given written informed consent to publish their case details.</p></sec><sec disp-level="1" id="S0007"><title>Authors contributions</title><p><bold>Christoffer Gebhardt:</bold> Conceptualization, project coordination, validation, writing-original draft, review and editing, supervision; <bold>Dirk Debus:</bold> Conceptualization, resources/cases, validation, writing-original draft, review and editing; <bold>Peter Rohrer:</bold> Conceptualization, resources, writing-original draft, review and editing; <bold>Katharina C. K&#228;hler:</bold> Conceptualization, resources, validation, writing- original draft, review and editing; <bold>Lukas Koch:</bold> Conceptualization, resources, writing-original draft, review and editing; <bold>Patrick Terheyden:</bold> Conceptualization, validation, resources, writing- original draft, review and editing; <bold>Van Anh Nguyen:</bold> Conceptualization, validation, resources, writing-original draft, review and editing;</p></sec><sec disp-level="1" id="S0011"><title>Writing assistance</title><p>Medical writing support was provided by Dipl.-Biol. Dipl.-Ing. Lydia Budiner from Budiner Consulting and was funded by Pierre Fabre Pharma Germany. However, the authors directed and are fully responsible for this manuscript&#8217;s content and editorial decisions.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0008"><title>Disclosure statement</title><p>C. Gebhardt states research support by BMS, Novartis, Pierre-Fabre, Regeneron and Sanofi, membership of the advisory board of BioNTech, BMS, Immunocore, MSD, Novartis, Pierre-Fabre, Regeneron, Sanofi, SUN Pharma, Sysmex, and honoraria by BMS, GSK, Immunocore, MSD, Novartis, Pierre-Fabre, Regeneron, Sanofi, SUN Pharma, Sysmex, he received travel expenses by BMS, Pierre-Fabre, SUN Pharma, he is board member of the DeCOG (ADO), unpaid, of the Hiege Stiftung &#8211; Die Deutsche Hautkrebsstiftung, unpaid and of the the Roggenbuck Stiftung, unpaid, additionally he is a Co-Founder of Dermagnostix and Dermagnostix R&amp;D; D. Debus declares funding received by Pierre Fabre, consulting fees from MSD, BMS, Sanofi, Novartis, Pierre Fabre, Kyowa Kirin, SUN, honoraria from MSD, BMS, Sanofi, Novartis, Pierre Fabre, Kyowa Kirin, SUN, and meeting and travel expenses from MSD, BMS, Sanofi, Novartis, Pierre Fabre, Kyowa Kirin, SUN, Pfizer, Boehringer, Celltrion, he participated in advisory boards of MSD, BMS, Sanofi, Novartis, Pierre Fabre, Kyowa Kirin, SUN; P. Rohrer declares having received support for meeting attendance and travel expenses by Pierre Fabre; K.C. K&#228;hler declares consulting and advisory roles with BMS, MSD, Pierre Fabre, Philogen, Sun Pharma, research funding provided by Novartis, travel, meeting attendance support and expenses by BMS, MSD, Novartis, Roche, Pierre Fabre, Sun Pharma; L. Koch declares grants for research received by Pierre Fabre, honoraria received in 2023 from Pierre Fabre for presentations and support for meeting attendance and expenses from Pierre Fabre in 2023; P. Terheyden declares consluting fees from Almirall, Biotest, Bristol-Myers Squibb, Sanofi, honoraria paid by Almirall, Bristol-Myers Squibb, L&#8217;Or&#233;al, Novartis, Pierre-Fabre, Merck Serono, Sanofi, Roche, Kyowa Kirin, Biofrontera, 4SC, support for attending meetings and expenses for travel paid by Bristol Myers Squibb, Pierre Fabre; V.A. Nguyen declares consulting fees from BMS, MSD, Merck, Novartis, Pierre Fabre, Roche, Sanofi, honoraria from BMS, MSD, Novartis, Pierre Fabre, Roche and meeting support and expenses provided by BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi.</p></sec><sec sec-type="data-availability" disp-level="1" id="S0012"><title>Data availability statement</title><p>The data supporting this study&#8217;s findings are available from the corresponding author upon reasonable request.</p></sec><ref-list><title>References</title><p>Papers of special note have been highlighted as either of interest (&#8226;) or of considerable interest (&#8226;&#8226;) to readers.</p><ref id="CIT0001"><label>1</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Cancer Information System [Internet]</collab></person-group>. <article-title>Estimated cancer incidence in Europe</article-title>; [cited 2025 Jul 15]. Available from: <ext-link xlink:href="https://ecis.jrc.ec.europa.eu" ext-link-type="uri">https://ecis.jrc.ec.europa.eu</ext-link></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Cancer Information System</collab></person-group>. <article-title>Estimated cancer mortality</article-title>; [cited 2025 Jul 15]. Available from: <ext-link xlink:href="https://ecis.jrc.ec.europa.eu" ext-link-type="uri">https://ecis.jrc.ec.europa.eu</ext-link></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Forsea</surname><given-names>AM.</given-names></string-name></person-group><article-title>Melanoma epidemiology and early detection in Europe: diversity and disparities</article-title>. <source>Dermatol Pract Concept</source>. <year>2020</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e2020033</fpage>. doi: <pub-id pub-id-type="doi">10.5826/dpc.1003a33</pub-id><pub-id pub-id-type="pmid">32642304</pub-id><pub-id pub-id-type="pmcid">PMC7319793</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Allemani</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Matsuda</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Di Carlo</surname><given-names>V</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10125</issue>):<fpage>1023</fpage>&#8211;<lpage>1075</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33326-3</pub-id><pub-id pub-id-type="pmid">29395269</pub-id><pub-id pub-id-type="pmcid">PMC5879496</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akbani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kadir</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Akdemir</surname><given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Genomic classification of cutaneous melanoma</article-title>. <source>Cell</source>. <year>2015</year>;<volume>161</volume>(<issue>7</issue>):<fpage>1681</fpage>&#8211;<lpage>1696</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2015.05.044</pub-id><pub-id pub-id-type="pmid">26091043</pub-id><pub-id pub-id-type="pmcid">PMC4580370</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gershenwald</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Scolyer</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Hess</surname><given-names>KR</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual</article-title>. <source>CA Cancer J Clin</source>. <year>2017</year>;<volume>67</volume>(<issue>6</issue>):<fpage>472</fpage>&#8211;<lpage>492</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21409.2</pub-id><pub-id pub-id-type="pmid">29028110</pub-id><pub-id pub-id-type="pmcid">PMC5978683</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Robert-Koch Institute [Internet]</collab></person-group>. <article-title>Berlin: [Cancer in Germany 2019/2020];</article-title> [cited 2025 Jul 15]. Available from: <ext-link xlink:href="http://www.krebsdaten.de" ext-link-type="uri">www.krebsdaten.de</ext-link></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davies</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>McIntyre</surname><given-names>S</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Prognostic factors for survival in melanoma patients with brain metastases</article-title>. <source>Cancer</source>. <year>2011</year>;<volume>117</volume>(<issue>8</issue>):<fpage>1687</fpage>&#8211;<lpage>1696</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.25634</pub-id><pub-id pub-id-type="pmid">20960525</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Margolin</surname><given-names>KA.</given-names></string-name></person-group><article-title>Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies</article-title>. <source>Am Soc Clin Oncol Educ Book</source>. <year>2013</year>;<volume>33</volume>(<issue>33</issue>):<fpage>393</fpage>&#8211;<lpage>398</lpage>. doi: <pub-id pub-id-type="doi">10.14694/EdBook_AM.2013.33.393</pub-id><pub-id pub-id-type="pmid">23714558</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Kirkwood</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Grob</surname><given-names>JJ</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>The role of BRAF V600 mutation in melanoma</article-title>. <source>J Transl Med</source>. <year>2012</year>;<volume>10</volume>(<issue>1</issue>):<fpage>85</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1479-5876-10-85</pub-id><pub-id pub-id-type="pmid">22554099</pub-id><pub-id pub-id-type="pmcid">PMC3391993</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sanchez-Vega</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mina</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Armenia</surname><given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Oncogenic signaling pathways in The Cancer Genome Atlas</article-title>. <source>Cell</source>. <year>2018</year>;<volume>173</volume>(<issue>2</issue>):<fpage>321</fpage>&#8211;<lpage>337.e10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2018.03.035</pub-id><pub-id pub-id-type="pmid">29625050</pub-id><pub-id pub-id-type="pmcid">PMC6070353</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bradish</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></string-name></person-group><article-title>Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach</article-title>. <source>Hum Pathol</source>. <year>2014</year>;<volume>45</volume>(<issue>7</issue>):<fpage>1315</fpage>&#8211;<lpage>1326</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.humpath.2014.04.001</pub-id><pub-id pub-id-type="pmid">24856851</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ponti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pellacani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tomasi</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations</article-title>. <source>J Clin Pathol</source>. <year>2013</year>;<volume>66</volume>(<issue>5</issue>):<fpage>441</fpage>&#8211;<lpage>445</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jclinpath-2012-201345</pub-id><pub-id pub-id-type="pmid">23463675</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>McArthur</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Dr&#233;no</surname><given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2016</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1248</fpage>&#8211;<lpage>1260</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(16)30122-X</pub-id><pub-id pub-id-type="pmid">27480103</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Karaszewska</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schachter</surname><given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Improved overall survival in melanoma with combined dabrafenib and trametinib</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>1</issue>):<fpage>30</fpage>&#8211;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1412690</pub-id><pub-id pub-id-type="pmid">25399551</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Stroyakovskiy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gogas</surname><given-names>H</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>9992</issue>):<fpage>444</fpage>&#8211;<lpage>451</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60898-4</pub-id><pub-id pub-id-type="pmid">26037941</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schadendorf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dummer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Flaherty</surname><given-names>KT</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma</article-title>. <source>Eur J Cancer</source>. <year>2024</year>;<volume>204</volume>:<fpage>114073</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2024.114073</pub-id><pub-id pub-id-type="pmid">38723373</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dummer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Flaherty</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>COLUMBUS 5-year update: a randomized, open-label, phase III Trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>36</issue>):<fpage>4178</fpage>&#8211;<lpage>4188</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.21.02659</pub-id><pub-id pub-id-type="pmid">35862871</pub-id><pub-id pub-id-type="pmcid">PMC9916040</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Grob</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Stroyakovskiy</surname><given-names>D</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>381</volume>(<issue>7</issue>):<fpage>626</fpage>&#8211;<lpage>636</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1904059</pub-id><pub-id pub-id-type="pmid">31166680</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: opdivo, nivolumab</article-title>; [cited 2025 Jul 15]. Available from: opdivo-epar-product-information_en.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: keytruda, INN-pembrolizumab</article-title>; [cited 2025 Jul 19]. Available from: keytruda-epar-product-information_en.pdf</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: yervoy, ipilimumab</article-title>; [cited 2025 Jul 19]. Available from: yervoy-epar-product-information_en.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: tafinlar, INN-dabrafenib</article-title>; [cited 2025 Jul 19]. Available from: tafinlar-epar-product-information_en.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: mekinist, INN-trametinib</article-title>; [cited 2025 Jul 19]. Available from: mekinist-epar-product-information_en.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: zelboraf, INN-vemurafenib</article-title>; [cited 2025 Jul 19]. Available from: zelboraf-epar-product-information_en.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: cotellic, INN-cobimetinib</article-title>; [cited 2025 Jul 19]. Available from: cotellic-epar-product-information_en.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: mektovi, INN-binimetinib</article-title>; [cited <year>2025</year> Jul 19]. Available from: mektovi-epar-product-information_de.pdf (europa.eu)</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe: product information: bravtovi, INN-binimetinib</article-title>; [cited <year>2025</year> Jul 19]. Available from: <ext-link xlink:href="https://braftovi-epar-product-information_en.pdf" ext-link-type="uri">braftovi-epar-product-information_en.pdf</ext-link> (europa.eu)</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency (EMA) [Internet]</collab></person-group>. <article-title>Europe. Opdualag | European Medicines Agency (EMA)</article-title>; [cited <year>2024</year> Nov]. Available from: <ext-link xlink:href="https://Opdualag-epar-product-information_en.pdf" ext-link-type="uri">Opdualag-epar-product-information_en.pdf</ext-link> last</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amaral</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ottaviano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arance</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source>. <year>2025</year>;<volume>36</volume>(<issue>1</issue>):<fpage>10</fpage>&#8211;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2024.11.006</pub-id><pub-id pub-id-type="pmid">39550033</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Brady</surname><given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Five-year outcomes with nivolumab in patients with wild-Type <italic toggle="yes">BRAF</italic> advanced melanoma</article-title>. <source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>33</issue>):<fpage>3937</fpage>&#8211;<lpage>3946</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.20.00995</pub-id><pub-id pub-id-type="pmid">32997575</pub-id><pub-id pub-id-type="pmcid">PMC7676881</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ribas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schachter</surname><given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study</article-title>. <source>Lancet Oncol</source>. <year>2019</year>;<volume>20</volume>(<issue>9</issue>):<fpage>1239</fpage>&#8211;<lpage>1251</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(19)30388-2</pub-id><pub-id pub-id-type="pmid">31345627</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez</surname><given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>2</issue>):<fpage>127</fpage>&#8211;<lpage>137</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.21.02229</pub-id><pub-id pub-id-type="pmid">34818112</pub-id><pub-id pub-id-type="pmcid">PMC8718224</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tawbi</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Schadendorf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lipson</surname><given-names>EJ</given-names></string-name>, <collab>In</collab></person-group>., et&#160;al. <article-title>Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>1</issue>):<fpage>24</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2109970</pub-id><pub-id pub-id-type="pmid">34986285</pub-id><pub-id pub-id-type="pmcid">PMC9844513</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Hodi</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Lipson</surname><given-names>EJ</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Overall survival and response with nivolumab and relatlimab in advanced melanoma</article-title>. <source>NEJM Evid</source>. <year>2023</year>;<volume>2</volume>(<issue>4</issue>):<fpage>EVIDoa2200239</fpage>. doi: <pub-id pub-id-type="doi">10.1056/EVIDoa2200239</pub-id><pub-id pub-id-type="pmid">38320023</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garbe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Amaral</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Peris</surname><given-names>K</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment&#8212;update 2022</article-title>. <source>Eur J Cancer</source>. <year>2022</year>;<volume>170</volume>:<fpage>256</fpage>&#8211;<lpage>284</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2022.04.018</pub-id><pub-id pub-id-type="pmid">35623961</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grote</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Debus</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bluhm</surname><given-names>L</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Retrospective survey of individual case reports on treatment situations in patients with locally advanced or metastatic, BRAFV600-mutated melanoma with encorafenib and binimetinib (REMINISCENCE)</article-title>. <source>J German Soc Dermatol</source>. <year>2022</year>(ADO Congress Abstract Supplement S3);<volume>20</volume>(<issue>suppl3</issue>):<fpage>30</fpage>.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><string-name name-style="western"><surname>Rohrer</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Debus</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Grote</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Retrospective single case reports on the treatment of patients with advanced BRAF[-mutated malignant melanoma with encorafenib plus binimetinib (REMINISCENCE). Focus on patients with brain metastases</article-title>. Presented at the <source>19th EADO Congress, 2023 April 20-22, Rome, Italy, Proceedings of the 19th EADO Congress/ Book-of-Abstracts;</source> [cited 2025 Jul 10]. Available from: <ext-link xlink:href="https://eado.org/files/2023/05/Book-of-Abstracts_EADO2023_v3.pdf" ext-link-type="uri">https://eado.org/files/2023/05/Book-of-Abstracts_EADO2023_v3.pdf</ext-link></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Le Rhun</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Weller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Anders</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>&#8222;Symptomatic &#8220;menlanoma brain metastases: a call for clear definitions and adoption of standardized tools</article-title>. <source>Eur J Cancer</source>. <year>2024</year>;<volume>208</volume>:<fpage>114202</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2024.114202</pub-id><pub-id pub-id-type="pmid">38991283</pub-id><pub-id pub-id-type="pmcid">PMC12290799</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hajihossainlou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Vasileva</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Manthri</surname><given-names>S</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern</article-title>. <source>BMJ Case Rep</source>. <year>2021</year>;<volume>14</volume>(<issue>8</issue>):<fpage>e243764</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bcr-2021-243764</pub-id><pub-id pub-id-type="pmcid">PMC8383870</pub-id><pub-id pub-id-type="pmid">34426425</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YP</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>WC</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Immune checkpoint inhibitor-induced myasthenia gravis</article-title>. <source>Front Neurol</source>. <year>2020</year>;<volume>11</volume>:<fpage>634</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2020.00634</pub-id><pub-id pub-id-type="pmid">32765397</pub-id><pub-id pub-id-type="pmcid">PMC7378376</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lau</surname><given-names>KHV</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>IH</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab</article-title>. <source>Muscle Nerve</source>. <year>2016</year>;<volume>54</volume>(<issue>1</issue>):<fpage>157</fpage>&#8211;<lpage>161</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mus.25141</pub-id><pub-id pub-id-type="pmid">27065302</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonzalez</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Puwanant</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Myasthenia triggered by immune checkpoint inhibitors: new case and literature review</article-title>. <source>Neuromuscul Disord</source>. <year>2017</year>;<volume>27</volume>(<issue>3</issue>):<fpage>266</fpage>&#8211;<lpage>268</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nmd.2017.01.002</pub-id><pub-id pub-id-type="pmid">28109638</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Guideline program Oncology provided by AWMF [Internet]</collab></person-group>. <article-title>Germany: [Diagnostics, therapy and follow-up care in melanoma, long version no. 3.3, 2020, AWMF registration no.: 032/024OL];</article-title> [cited 2025 Jul 19]. Available from: <ext-link xlink:href="http://www.leitlinienprogramm%20onkologie.de/leitlinien/melanom/" ext-link-type="uri">www.leitlinienprogramm onkologie.de/leitlinien/melanom/</ext-link></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schachter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ribas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>390</volume>(<issue>10105</issue>):<fpage>1853</fpage>&#8211;<lpage>1862</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(17)31601-X</pub-id><pub-id pub-id-type="pmid">28822576</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spain</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Walls</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Messiou</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series</article-title>. <source>Cancer Immunol Immunother</source>. <year>2017</year>;<volume>66</volume>(<issue>1</issue>):<fpage>113</fpage>&#8211;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00262-016-1926-2</pub-id><pub-id pub-id-type="pmid">27838762</pub-id><pub-id pub-id-type="pmcid">PMC11028695</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis</article-title>. <source>Front Immunol</source>. <year>2021</year>;<volume>12</volume>:<fpage>730320</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2021.730320</pub-id><pub-id pub-id-type="pmid">34646270</pub-id><pub-id pub-id-type="pmcid">PMC8503641</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dietz</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Weinmann</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Salama</surname><given-names>AK.</given-names></string-name></person-group><article-title>Checkpoint inhibitors in melanoma patients with underlying autoimmune disease</article-title>. <source>Cancer Manag Res</source>. <year>2021</year>;<volume>13</volume>:<fpage>8199</fpage>&#8211;<lpage>8208</lpage>. doi: <pub-id pub-id-type="doi">10.2147/CMAR.S283217</pub-id><pub-id pub-id-type="pmid">34754240</pub-id><pub-id pub-id-type="pmcid">PMC8572012</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abdel-Wahab</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lopez-Olivo</surname><given-names>MA</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Use of checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>168</volume>(<issue>2</issue>):<fpage>121</fpage>&#8211;<lpage>130</lpage>. doi: <pub-id pub-id-type="doi">10.7326/M17-2073</pub-id><pub-id pub-id-type="pmid">29297009</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>S</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study</article-title>. <source>Lancet Oncol</source>. <year>2018</year>;<volume>19</volume>(<issue>5</issue>):<fpage>672</fpage>&#8211;<lpage>681</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30139-6</pub-id><pub-id pub-id-type="pmid">29602646</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>S</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo&#8201;+&#8201;ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets)</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>15_suppl</issue>):<fpage>9508</fpage>&#8211;<lpage>9508</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.9508</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tawbi</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Forsyth</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Hodi</surname><given-names>FS</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)</article-title>. <source>Neuro Oncol</source>. <year>2021</year>;<volume>23</volume>(<issue>11</issue>):<fpage>1961</fpage>&#8211;<lpage>1973</lpage>. doi: <pub-id pub-id-type="doi">10.1093/neuonc/noab094</pub-id><pub-id pub-id-type="pmid">33880555</pub-id><pub-id pub-id-type="pmcid">PMC8563325</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tawbi</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Forsyth</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Hodi</surname><given-names>FS</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study</article-title>. <source>Lancet Oncol</source>. <year>2021</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1692</fpage>&#8211;<lpage>1704</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(21)00545-3</pub-id><pub-id pub-id-type="pmid">34774225</pub-id><pub-id pub-id-type="pmcid">PMC9328029</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Di Giacomo</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Del Vecchio</surname><given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. In</article-title>. <source>Eur J Cancer</source>. <year>2024</year>;<volume>199</volume>:<fpage>113531</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2024.113531</pub-id><pub-id pub-id-type="pmid">38271746</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Di Giacomo</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Del Vecchio</surname><given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases</article-title>. <source>Clin Cancer Res</source>. <year>2021</year>;<volume>27</volume>(<issue>17</issue>):<fpage>4737</fpage>&#8211;<lpage>4745</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1046</pub-id><pub-id pub-id-type="pmid">34112708</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kluger</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Mahajan</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial</article-title>. <source>J Clin Oncol</source>. <year>2019</year>;<volume>37</volume>(<issue>1</issue>):<fpage>52</fpage>&#8211;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.18.00204</pub-id><pub-id pub-id-type="pmid">30407895</pub-id><pub-id pub-id-type="pmcid">PMC6354772</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gaudy-Marqueste</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Carron</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Delsanti</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>On demand gamma-knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>(<issue>10</issue>):<fpage>2086</fpage>&#8211;<lpage>2091</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdu266</pub-id><pub-id pub-id-type="pmid">25057167</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dummer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Queirolo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gerard Duhard</surname><given-names>P</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study</article-title>. <source>Lancet Oncol</source>. <year>2023</year>;<volume>24</volume>(<issue>12</issue>):<fpage>e461</fpage>&#8211;<lpage>e471</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(23)00334-0</pub-id><pub-id pub-id-type="pmid">37459873</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dummer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Levesque</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bellini</surname><given-names>E</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation&#8211;positive melanoma with central nervous system (CNS) metastases (mets): final results and exploratory biomarker analysis from the phase 2 TRICOTEL study</article-title>. <source>J Clin Oncol</source>. <year>2024</year>;<volume>42</volume>(<issue>16_suppl</issue>):<fpage>9550</fpage>&#8211;<lpage>9550</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2024.42.16_suppl.9550</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McArthur</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Maio</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arance</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study</article-title>. <source>Ann Oncol</source>. <year>2017</year>;<volume>28</volume>(<issue>3</issue>):<fpage>634</fpage>&#8211;<lpage>641</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdw641</pub-id><pub-id pub-id-type="pmid">27993793</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Trefzer</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname><given-names>MA</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2012</year>;<volume>13</volume>(<issue>11</issue>):<fpage>1087</fpage>&#8211;<lpage>1095</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(12)70431-X</pub-id><pub-id pub-id-type="pmid">23051966</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kirkwood</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Trefzer</surname><given-names>U</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>BREAK-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)</article-title>. <source>JCO</source>. <year>2012</year>;<volume>30</volume>(<issue>15_suppl</issue>):<fpage>8501</fpage>&#8211;<lpage>8501</lpage>. doi: <pub-id pub-id-type="doi">10.1200/jco.2012.30.15_suppl.8501</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davies</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Saiag</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2017</year>;<volume>18</volume>(<issue>7</issue>):<fpage>863</fpage>&#8211;<lpage>873</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30429-1</pub-id><pub-id pub-id-type="pmid">28592387</pub-id><pub-id pub-id-type="pmcid">PMC5991615</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#225;rquez-Rodas</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>&#193;lvarez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Arance</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)</article-title>. <source>Neuro Oncol</source>. <year>2024</year>;<volume>26</volume>(<issue>11</issue>):<fpage>2074</fpage>&#8211;<lpage>2083</lpage>. doi: <pub-id pub-id-type="doi">10.1093/neuonc/noae116</pub-id><pub-id pub-id-type="pmid">38946469</pub-id><pub-id pub-id-type="pmcid">PMC11534317</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seymour</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bogaerts</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics</article-title>. <source>Lancet Oncol</source>. <year>2017</year>;<volume>18</volume>(<issue>3</issue>):<fpage>e143</fpage>&#8211;<lpage>e152</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30074-8</pub-id><pub-id pub-id-type="pmid">28271869</pub-id><pub-id pub-id-type="pmcid">PMC5648544</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marquez-Rodas</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Arance Fernandez</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Berciano Guerrero</surname><given-names>MA</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial. E-BRAIN</article-title>. <source>Ann Oncol</source>. <year>2022</year>;<volume>33</volume>:<fpage>S926</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.952</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larkin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez</surname><given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Five-year survival with combined nivolumab and ipilimumab in advanced melanoma</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>381</volume>(<issue>16</issue>):<fpage>1535</fpage>&#8211;<lpage>1546</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1910836</pub-id><pub-id pub-id-type="pmid">31562797</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ribas</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hamid</surname><given-names>O</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma</article-title>. <source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>17</issue>):<fpage>1668</fpage>&#8211;<lpage>1674</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2017.75.6270</pub-id><pub-id pub-id-type="pmid">29283791</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frederick</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Piris</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cogdill</surname><given-names>AP</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma</article-title>. <source>Clin Cancer Res</source>. <year>2013</year>;<volume>19</volume>(<issue>5</issue>):<fpage>1225</fpage>&#8211;<lpage>1231</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1630</pub-id><pub-id pub-id-type="pmid">23307859</pub-id><pub-id pub-id-type="pmcid">PMC3752683</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keilholz</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Dummer</surname><given-names>R</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO-Guidelines Committee. Expert Consensus</article-title>. <source>Ann Oncol</source>. <year>2020</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1435</fpage>&#8211;<lpage>1448</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2020.07.004</pub-id><pub-id pub-id-type="pmid">32763453</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reijers</surname><given-names>ILM</given-names></string-name>, <string-name name-style="western"><surname>Rozeman</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Wilgenhof</surname><given-names>S</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: a retrospective single-centre experience in patients with BRAF-mutated melanoma</article-title>. <source>Pigment Cell Melanoma Res</source>. <year>2020</year>;<volume>33</volume>(<issue>3</issue>):<fpage>498</fpage>&#8211;<lpage>506</lpage>. doi: <pub-id pub-id-type="doi">10.1111/pcmr.12835</pub-id><pub-id pub-id-type="pmid">31646741</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haas</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Elewaut</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gerard</surname><given-names>CL</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma</article-title>. <source>Nat Cancer</source>. <year>2021</year>;<volume>2</volume>(<issue>7</issue>):<fpage>693</fpage>&#8211;<lpage>708</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s43018-021-00221-9</pub-id><pub-id pub-id-type="pmid">35121945</pub-id><pub-id pub-id-type="pmcid">PMC7613740</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Chmielowski</surname><given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>(<issue>2</issue>):<fpage>186</fpage>&#8211;<lpage>197</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.22.01763</pub-id><pub-id pub-id-type="pmid">36166727</pub-id><pub-id pub-id-type="pmcid">PMC9839305</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Casula</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bulgarelli</surname><given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>146</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-023-44475-6</pub-id><pub-id pub-id-type="pmid">38167503</pub-id><pub-id pub-id-type="pmcid">PMC10761671</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Mandal&#224;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferrucci</surname><given-names>PF</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>(<issue>2</issue>):<fpage>212</fpage>&#8211;<lpage>221</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.21.02961</pub-id><pub-id pub-id-type="pmid">36049147</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dutriaux</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Oppong</surname><given-names>FB</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF -V600E/K-mutated melanoma: the primary analysis of an EORTC randomized phase II study (EBIN)</article-title>. <source>J Clin Oncol</source>. <year>2024</year>;<volume>42</volume>(<issue>17_suppl</issue>):<fpage>LBA9503</fpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2024.42.17_suppl.LBA9503</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schadendorf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gogas</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kandolf- Sekulovic</surname><given-names>L</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial</article-title>. <source>Ann Oncol</source>. <year>2024</year>;<volume>35</volume>(<issue>Suppl 2</issue>):<fpage>S1235</fpage>&#8211;<lpage>S1236</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2024.08.2286</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Livingstone</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gogas</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kandolf-Sekulovic</surname><given-names>L</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: the ImmunoCobiVem phase 2 randomised trial</article-title>. <source>Eur J Cancer</source>. <year>2023</year>;<volume>190</volume>:<fpage>112941</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2023.112941</pub-id><pub-id pub-id-type="pmid">37482012</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scaini</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Catoni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Poggiana</surname><given-names>C</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance</article-title>. <source>NPJ Precis Oncol</source>. <year>2024</year>;<volume>8</volume>(<issue>1</issue>):<fpage>78</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41698-024-00567-0</pub-id><pub-id pub-id-type="pmid">38548846</pub-id><pub-id pub-id-type="pmcid">PMC10978909</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seth</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Messersmith</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>V</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Systemic therapy for melanoma: ASCO guideline</article-title>. <source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>33</issue>):<fpage>3947</fpage>&#8211;<lpage>3970</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.20.00198</pub-id><pub-id pub-id-type="pmid">32228358</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grant</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Gillespie</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Karamian</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Evolving treatment paradigms for melanoma brain metastases: a systematic review of current modalities</article-title>. <source>Clin Neurol Neurosurg</source>. <year>2025</year>;<volume>257</volume>:<fpage>109025</fpage>. Epub ahead of print. doi: <pub-id pub-id-type="doi">10.1016/j.clineuro.2025.109025</pub-id><pub-id pub-id-type="pmid">40609368</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krist</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Naik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>CM</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Management of brain metastasis. Surgical resection versus stereotactic radiotherapy: a meta-analysis</article-title>. <source>Neurooncol Adv</source>. <year>2022</year>;<volume>4</volume>(<issue>1</issue>):<fpage>vdac033</fpage>. doi: <pub-id pub-id-type="doi">10.1093/noajnl/vdac033</pub-id><pub-id pub-id-type="pmid">35386568</pub-id><pub-id pub-id-type="pmcid">PMC8982204</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mandal&#224;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amaral</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Rutkowski</surname><given-names>P</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study</article-title>. <source>Eur J Cancer</source>. <year>2025</year>;<volume>225</volume>:<fpage>115567</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2025.115567</pub-id><pub-id pub-id-type="pmid">40505525</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Clinicaltrials.gov [Internet]</collab></person-group>. <article-title>Bethesda (MD): <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT04511013">NCT04511013</ext-link>&#8212;a study to compare the administration of Encorafenib&#8201;+&#8201;Binimetinib&#8201;+&#8201;Nivolumab versus Ipilimumab&#8201;+&#8201;Nivolumab in BRAF-V600 mutant melanoma with brain metastases</article-title>; [cited 2025 Jul 26]. Available from: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT04511013" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04511013</ext-link></mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Clinicaltrials.gov [Internet]</collab></person-group>. <article-title>Bethesda (MD): <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03340129">NCT03340129</ext-link>- anti-PD 1 brain collaboration&#8201;+&#8201;radiotherapy extension (ABC-X Study) (ABC-X)</article-title>; [cited 2025 Jul 26]. Available from: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT03340129" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03340129</ext-link></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gracie</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Atenafu</surname><given-names>EG</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis</article-title>. <source>Eur J Cancer</source>. <year>2021</year>;<volume>158</volume>:<fpage>191</fpage>&#8211;<lpage>207</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2021.09.019</pub-id><pub-id pub-id-type="pmid">34757258</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rhodin</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Therien</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Circulating tumor DNA in high-risk stage II/III cutaneous melanoma: a feasibility study</article-title>. <source>Ann Surg Oncol</source>. <year>2025</year>;<volume>32</volume>(<issue>7</issue>):<fpage>5292</fpage>&#8211;<lpage>5299</lpage>. doi: <pub-id pub-id-type="doi">10.1245/s10434-025-17194-z</pub-id><pub-id pub-id-type="pmid">40146490</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ayers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lunceford</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nebozhyn</surname><given-names>M</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>IFN-&#947;-related mRNA profile predicts clinical response to PD-1 blockade</article-title>. <source>J Clin Invest</source>. <year>2017</year>;<volume>127</volume>(<issue>8</issue>):<fpage>2930</fpage>&#8211;<lpage>2940</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI91190</pub-id><pub-id pub-id-type="pmid">28650338</pub-id><pub-id pub-id-type="pmcid">PMC5531419</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amaral</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chatziioannou</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Nuebling</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Risk stratification using the Merlin assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy</article-title>. <source>Eur J Cancer</source>. <year>2025</year>;<volume>220</volume>:<fpage>115372</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2025.115372</pub-id><pub-id pub-id-type="pmid">40274320</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reschke</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dumann</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ziemer</surname><given-names>M.</given-names></string-name></person-group><article-title>Risk stratification and clinical characteristics of patients with late recurrence of melanoma (&gt;10 years)</article-title>. <source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>7</issue>):<fpage>2026</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm11072026</pub-id><pub-id pub-id-type="pmid">35407631</pub-id><pub-id pub-id-type="pmcid">PMC9000041</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Karasaki</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Farma</surname><given-names>JM.</given-names></string-name></person-group><article-title>The use of gene expression profiling and biomarkers in melanoma diagnosis and recurrence prediction: implications for surveillance and treatment</article-title>. <source>Cancers (Basel)</source>. <year>2024</year>;<volume>16</volume>(<issue>3</issue>):<fpage>583</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers16030583</pub-id><pub-id pub-id-type="pmid">38339333</pub-id><pub-id pub-id-type="pmcid">PMC10854922</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garutti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Polesel</surname><given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: a systematic review and meta-analysis</article-title>. <source>Heliyon</source>. <year>2024</year>;<volume>10</volume>(<issue>12</issue>):<fpage>e32433</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e32433</pub-id><pub-id pub-id-type="pmid">39183829</pub-id><pub-id pub-id-type="pmcid">PMC11341338</pub-id></mixed-citation></ref></ref-list><ref-list><title>Reference annotations</title><ref id="CIT0093"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Schade&#8202;ndorf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dum&#8202;mer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Flaherty</surname><given-names>KT</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma</article-title>. <source>Eur J Cancer</source>. <year>2024</year>;<volume>204</volume>:<fpage>114073</fpage>.<pub-id pub-id-type="pmid">38723373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2024.114073</pub-id></mixed-citation><note><p>
<bold>The COLUMBUS-7 study is a landmark in melanoma research because it provides long-term evidence&#8212;spanning seven years&#8212;on the effectiveness and safety of targeted therapies for patients with BRAF V600E/K-mutant metastatic melanoma.</bold>
</p></note></ref><ref id="CIT0094"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Amaral</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ottaviano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arance</surname><given-names>A</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source>. <year>2025</year>;<volume>36</volume>(<issue>1</issue>):<fpage>10</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">39550033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.11.006</pub-id></mixed-citation><note><p>
<bold>Together with Part 1 of this guideline (this publication provides the latest diagnostic and therapy guidelines in Europe that are valid until the end of 2026.</bold>
</p></note></ref><ref id="CIT0095"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Haas</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Elewaut</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gerard</surname><given-names>CL</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma</article-title>. <source>Nat Cancer</source>. <year>2021</year>;<volume>2</volume>(<issue>7</issue>):<fpage>693</fpage>&#8211;<lpage>708</lpage>.<pub-id pub-id-type="pmid">35121945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-021-00221-9</pub-id><pub-id pub-id-type="pmcid">PMC7613740</pub-id></mixed-citation><note><p>
<bold>This study by Haas et&#160;al. (2021) is a game-changer in understanding how melanoma evolves under treatment pressure.</bold>
</p></note></ref><ref id="CIT0096"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Chmielowski</surname><given-names>B</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>(<issue>2</issue>):<fpage>186</fpage>&#8211;<lpage>197</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.22.01763</pub-id><pub-id pub-id-type="pmid">36166727</pub-id><pub-id pub-id-type="pmcid">PMC9839305</pub-id></mixed-citation><note><p>
<bold>The DREAMseq trial is a pivotal study that reshaped how clinicians approach treatment sequencing in advanced BRAF V600-mutant melanoma. It showed that treatment sequencing matter and Influences guidelines and real-world practice for managing BRAF-mutant melanoma.</bold>
</p></note></ref><ref id="CIT0097"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Casula</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bulgarelli</surname><given-names>J</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>146</fpage>.<pub-id pub-id-type="pmid">38167503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44475-6</pub-id><pub-id pub-id-type="pmcid">PMC10761671</pub-id></mixed-citation><note><p>
<bold>The SECOMBIT trial is a cornerstone study in melanoma treatment strategy, especially for patients with BRAF V600-mutant metastatic melanoma. It explores how the sequence of therapies&#8212;immunotherapy vs. targeted therapy&#8212;can dramatically influence long-term survival.</bold>
</p></note></ref><ref id="CIT0098"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Robert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dutriaux</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Oppong</surname><given-names>FB</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF -V600E/K-mutated melanoma: the primary analysis of an EORTC randomized phase II study (EBIN)</article-title>. <source>JCO</source>. <year>2024</year>;<volume>42</volume>(<issue>17_suppl</issue>):<fpage>LBA9503</fpage>.</mixed-citation><note><p>
<bold>The EBIN trial specifically examines treatment outcomes after early switching&#8212;before disease progression&#8212;from a short course of targeted therapy (encorafenib&#8201;+&#8201;binimetinib) to immune checkpoint inhibitors (ipilimumab&#8201;+&#8201;nivolumab) compared to immunotherapy alone. Results suggests that targeted therapy induction may prime the tumor microenvironment for better response to immunotherapy.</bold>
</p></note></ref><ref id="CIT0099"><mixed-citation publication-type="journal"><bold>&#8226;</bold><person-group person-group-type="author"><string-name name-style="western"><surname>Livingstone</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gogas</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kandolf-Sekulovic</surname><given-names>L</given-names></string-name>, <etal>et&#160;al.</etal></person-group><article-title>Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: the ImmunoCobiVem phase 2 randomised trial</article-title>. <source>Eur J Cancer</source>. <year>2023</year>;<volume>190</volume>:<fpage>112941</fpage>.<pub-id pub-id-type="pmid">37482012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.112941</pub-id></mixed-citation><note><p>
<bold>ImmunoCobiVem trial suggests that timing matters and is challenging the results of EBIN trial for early switch.</bold>
</p></note></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>